147 results on '"Sophie Christin-Maitre"'
Search Results
2. Prevalence and characteristics of gonadoblastoma in a retrospective multi-center study with follow-up investigations of 70 patients with Turner syndrome and a 45,X/46,XY karyotype
- Author
-
Daphné Karila, Bruno Donadille, Juliane Léger, Claire Bouvattier, Anne Bachelot, Veronique Kerlan, Sophie Catteau-Jonard, Sylvie Salenave, Frédérique Albarel, Claire Briet, Regis Coutant, Aude Brac De La Perriere, Alexander Valent, Jean-Pierre Siffroi, Sophie Christin-Maitre, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Service d'endocrinologie diabétologie pédiatrique [CHU Debré], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), National Reference Network DSD DevGen, Service d'endocrinologie pédiatrique [CHU Bicêtre], Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), CHU Lille, Université de Lille, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Endocrinologie, diabète, maladies métaboliques (CHU Marseille, AP-HM), Assistance Publique - Hôpitaux de Marseille (APHM), Centre de référence des maladies rares de l'hypophyse (HYPO), Service d'Endocrinologie, Diabète et Maladies Métaboliques, Endocrinologie pédiatrique[CHU Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), Département de biologie et pathologie médicales [Gustave Roussy], Institut Gustave Roussy (IGR), Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse (AMMICa), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Centre National de la Recherche Scientifique (CNRS), Maladies génétiques d'expression pédiatrique (U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [APHP], Centre de référence des Maladies Endocriniennes Rares de la Croissance [CHU Saint-Antoine AP-HP] (CRMERC), Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], Centre de référence des maladies endocriniennes rares de la croissance et du développement [CHU Pitié-Salpêtrière], Service d'Endocrinologie et Médecine de la Reproduction [CHU Pitié-Salpêtrière], Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), UF de Génétique chromosomique [CHU Trousseau], and Couvet, Sandrine
- Subjects
Adult ,Ovarian Neoplasms ,Adolescent ,Mosaicism ,[SDV]Life Sciences [q-bio] ,Endocrinology, Diabetes and Metabolism ,Karyotype ,Turner Syndrome ,General Medicine ,[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics ,[SDV] Life Sciences [q-bio] ,Young Adult ,Endocrinology ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,Prevalence ,Humans ,Female ,Gonadoblastoma ,Child ,Follow-Up Studies - Abstract
Introduction A gonadectomy is currently recommended in patients with Turner syndrome (TS) and a 45,X/46,XY karyotype, due to a potential risk of gonadoblastoma (GB). However, the quality of evidence behind this recommendation is low. Objective This study aimed to evaluate the prevalence of GB, its characteristics, as well as its risk factors, according to the type of Y chromosomal material in the karyotype. Methods Our study within French rare disease centers included patients with TS and a 45,X/46,XY karyotype, without ambiguity of external genitalia. Clinical characteristics of the patients, their age at gonadectomy, and gonadal histology were recorded. The regions of the Y chromosome, the presence of TSPY regions, and the percentage of 45,X/46,XY mosaicism were evaluated. Results A total of 70 patients were recruited, with a median age of 29.5 years (21.0–36.0) at the end of follow-up. Fifty-eight patients had a gonadectomy, at a mean age of 15 ± 8 years. GB was present in nine cases. Two were malignant, which were discovered at the age of 14 and 32 years, without metastases. Neither the percentage of XY cells within the 45,X/46,XY mosaicism nor the number of TSPY copies was statistically different in patients with or without GB (P = 0.37). However, the entire Y chromosome was frequent in patients with GB (6/9). Conclusions In our study, including a large number of patients with 45,X/46,XY TS, the prevalence of gonadoblastoma is 12.8%. An entire Y chromosome appears as the main risk factor of GB and should favor early gonadectomy. Significant statement About 10% of patients with TS have a karyotype containing Y chromosomal material: 45,X/46,XY. Its presence is related to the risk of GB. Therefore, a prophylactic gonadectomy is currently recommended in such patients. However, the quality of evidence is low. Our objective was to evaluate the prevalence of GB according to the type of Y-chromosomal material. We found a prevalence of GB of 12.8% in a cohort of 70 TS patients. No sign of hyperandrogenism was observed. The entire Y chromosome was the most frequent type of Y-material in patients with GB. As the prognosis of these tumors was good, a delay of surgery might be discussed.
- Published
- 2022
- Full Text
- View/download PDF
3. Androgens and spermatogenesis
- Author
-
Sophie, Christin-Maitre and Jacques, Young
- Subjects
Male ,Disorder of Sex Development, 46,XY ,Endocrinology ,Endocrinology, Diabetes and Metabolism ,Testis ,Androgens ,Sperm Motility ,Animals ,Humans ,Testosterone ,General Medicine ,Follicle Stimulating Hormone ,Spermatogenesis - Abstract
Male infertility contributes to 50% of all cases of infertility. The main cause is low quality and quantity of sperm. In humans, spermatogenesis starts at the beginning of puberty and lasts lifelong. It is under the control of FSH and testicular androgens, and mainly testosterone (T), and therefore requires a normal gonadotroph axis, intratesticular T production by Leydig cells and functional androgen receptors (ARs) within testicular Sertoli cells. Various clinical cases illustrate the roles of T in human spermatogenesis. Men with complete congenital hypogonadotropic hypogonadism (HH) are usually azoospermic. Treatment by exogenous testosterone injection and FSH is not able to produce sperm. However, combined treatment with FSH and hCG is effective. This example shows that intratesticular T plays a major role in spermatogenesis. Furthermore, testicular histology of men with LH receptor mutations shows Leydig cell hypoplasia/agenesis/dysplasia with conserved Sertoli cell count. The sperm count is reduced, as in males with partial inactivating mutation of the androgen receptor. Some protocols of hormonal male contraception or exogenous androgen abuse induce negative feedback in the hypothalamic pituitary axis, decreasing FSH, LH and T levels and inducing sperm defects and testicular atrophy. The time to recovery after cessation of drug abuse is around 14 months for sperm output and 38 months for sperm motility. In summary, abnormal androgen production and/or AR signaling impairs spermatogenesis in humans. The minimal level of intratesticular T for normal sperm production is a matter of debate. Interestingly, some animal models showed that completely T-independent spermatogenesis is possible, potentially through strong FSH activation. Finally, recent data suggest important roles of prenatal life and minipuberty in adult spermatogenesis.
- Published
- 2022
- Full Text
- View/download PDF
4. Role of insulin resistance on fertility – Focus on polycystic ovary syndrome
- Author
-
Camille Vatier, Sophie Christin-Maitre, Corinne Vigouroux, Centre National de Référence des Pathologies Rares de l'Insulino-Sécrétion et de l'Insulino-Sensibilité [CHu Saint-Antoine] (PRISIS), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de référence des maladies endocriniennes rares de la croissance et du développement [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), and Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN)
- Subjects
Inulinorésistance ,Metabolic Syndrome ,Infertilité ,Endocrinology, Diabetes and Metabolism ,polycystic ovaries ,Ovaires polykystiques ,General Medicine ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,Fertility ,Endocrinology ,Adipokines ,Infertility ,Humans ,Insulin ,Female ,Obesity ,Insulin Resistance ,Polycystic Ovary Syndrome - Abstract
International audience; Several lines of evidence show that gonadal functions and insulin sensitivity display multifaceted relationships, which extend far beyond the well-known association between polycystic ovary syndrome (PCOS), obesity, and metabolic syndrome. In this brief review, we will summarize the main findings showing the pathophysiological role of insulin resistance in impairing reproductive functions. Extreme phenotypes of severe insulin resistance, due to primary defects in insulin receptor or to lipodystrophy syndromes, provide unique opportunities for the modeling of interactions between insulin signaling and ovarian endocrine functions. In addition, recent studies further suggest that common forms of dysfunctional adiposity, as well as altered production of adipokines, could underlie important pathophysiological links between metabolic syndrome and infertility.; De multiples relations existent entre les fonctions gonadiques et la sensibilité à l’insuline, allant bien au-delà de l’association bien connue entre le syndrome des ovaires polykystiques (SOPK), l’obésité et le syndrome métabolique. Dans cette revue, nous résumerons les principales découvertes montrant le rôle physiopathologique de l’insulino-résistance dans l’altération des fonctions reproductives. Les phénotypes extrêmes d’insulino-résistance sévère, dus à des altérations du récepteur de l’insuline ou à des syndromes lipodystrophiques, offrent des opportunités uniques pour la modélisation des interactions entre la signalisation de l’insuline et les fonctions ovariennes endocrines. En outre, des études récentes suggèrent que les formes communes de dysfonction adipocytaire et/ou d’altération de la production d’adipokines, pourraient être à l’origine de liens physiopathologiques importants entre le syndrome métabolique et l’infertilité.
- Published
- 2022
- Full Text
- View/download PDF
5. Characteristics of dilated aortas in patients with Turner syndrome: clinical, histological and cytogenetic analysis
- Author
-
Bruno Donadille, Valent Alexander, Amemiya Kisaki, Rive-le-gouard Nicolas, lecot-connan tatiana, Iserin Laurence, Achouh Paul, Sylvie Salenave, Bruneval Patrick, Siffroi Jean-Pierre, and Sophie Christin-Maitre
- Subjects
General Medicine - Published
- 2023
- Full Text
- View/download PDF
6. 18F-fluorocholine PET/CT detects parathyroid gland hyperplasia as well as adenoma: 401 PET/CTs in one center
- Author
-
Jean-Noël TALBOT, Sophie PÉRIÉ, Marc TASSART, Thierry DELBOT, Cyrielle AVELINE, Jules ZHANG-YIN, Khaldoun KERROU, Sébastien GAUJOUX, Isabelle WAGNER, Malika BENNIS, Fabrice MÉNÉGAUX, Sarah BRETON, Beatrix COCHAND-PRIOLLET, Sophie CHRISTIN-MAITRE, Lionel GROUSSIN, Jean-Philippe HAYMANN, Bertrand BAUJAT, Sona BALOGOVA, and Françoise MONTRAVERS
- Subjects
Radiology, Nuclear Medicine and imaging - Published
- 2023
- Full Text
- View/download PDF
7. Focus on Liver Function Abnormalities in Patients With Turner Syndrome: Risk Factors and Evaluation of Fibrosis Risk
- Author
-
Nathalie Bourcigaux, Emma Dubost, Jean-Claude Buzzi, Bruno Donadille, Christophe Corpechot, Armelle Poujol-Robert, and Sophie Christin-Maitre
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,Biochemistry (medical) ,Clinical Biochemistry ,Biochemistry - Abstract
ContextLiver function abnormalities (LFAs) have been described in patients with Turner syndrome (TS). Although a high risk of cirrhosis has been reported, there is a need to assess the severity of liver damage in a large cohort of adult patients with TS.ObjectiveEvaluate the types of LFAs and their respective prevalence, search for their risk factors, and evaluate the severity of liver impairment by using a noninvasive fibrosis marker.MethodsThis was a monocentric retrospective cross-sectional study. Data were collected during a day hospital visit. The main outcome measures were liver enzymes (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase), FIB-4 score, liver ultrasound imaging, elastography, and liver biopsies, when available.Results264 patients with TS were evaluated at a mean age of 31.15 ± 11.48 years. The overall prevalence of LFAs was 42.8%. The risk factors were age, body mass index, insulin resistance, and an X isochromosome (Xq). The mean FIB-4 sore of the entire cohort was 0.67 ± 0.41. Less than 10% of patients were at risk of developing fibrosis. Cirrhosis was observed in 2/19 liver biopsies. There was no significant difference in the prevalence of LFAs between premenopausal patients with natural cycles and those receiving hormone replacement therapy (P = .063). A multivariate analysis adjusted for age showed no statistically significant correlation between hormone replacement therapy and abnormal gamma-glutamyl transferase levels (P = .12).ConclusionPatients with TS have a high prevalence of LFA. However, 10% are at high risk of developing fibrosis. The FIB-4 score is useful and should be part of the routine screening strategy. Longitudinal studies and better interactions with hepatologists should improve our knowledge of liver disease in patients with TS.
- Published
- 2023
- Full Text
- View/download PDF
8. Impact of intra-uterine life on future health
- Author
-
Léa, Azoulay, Claire, Bouvattier, and Sophie, Christin-Maitre
- Subjects
Placenta ,Endocrinology, Diabetes and Metabolism ,General Medicine ,Endocrine Disruptors ,Epigenesis, Genetic ,Obesity, Maternal ,Endocrinology ,Pregnancy ,Risk Factors ,Prenatal Exposure Delayed Effects ,Humans ,Female ,Insulin Resistance ,Polycystic Ovary Syndrome - Abstract
Since the emergence of the concept of developmental origins of health and disease (DOHaD), suggested by Barker in the 1980s, numerous epidemiological studies in humans have confirmed the relationship between maternal obesity during pregnancy and the risk of offspring developing various chronic adult illnesses. These effects of intrauterine life are independent of inheritance of disease susceptibility genes and/or socio-economic factors. Regarding potential mechanisms, recent data from animal models suggests a role of insulin resistance early in development. Another potential mechanism, in the case of maternal obesity, is increased placental nutrient transfer. The DOHaD concept also includes fetal exposure to environmental endocrine disruptors (EEDs). A Danish group for the first time recently analyzed EED passage across the placenta in humans throughout pregnancy. This study showed different levels of bioaccumulation depending on the fetal organ, with greater vulnerability in male than female fetuses. Recent clinical studies suggested an association between fetal exposure to particular EEDs and precocious puberty, increased incidence of cryptorchidism and impaired sperm quality in adulthood. These modifications of the in-utero environment also appear to be responsible for epigenetic changes that are transmittable over several generations. A recent example of this is the demonstration of the transmission of polycystic ovary syndrome (PCOS) in mice. In summary, an increasing number of examples of the impact of intrauterine life on the health of offspring have appeared in recent years, illustrating the important role that endocrinologists can play in preventing particular pathologies in future generations.
- Published
- 2022
- Full Text
- View/download PDF
9. Identification of predictive criteria for pathogenic variants of primary bilateral macronodular adrenal hyperplasia (PBMAH) gene ARMC5 in 352 unselected patients
- Author
-
Lucas Bouys, Anna Vaczlavik, Anne Jouinot, Patricia Vaduva, Stéphanie Espiard, Guillaume Assié, Rossella Libé, Karine Perlemoine, Bruno Ragazzon, Laurence Guignat, Lionel Groussin, Léopoldine Bricaire, Isadora Pontes Cavalcante, Fidéline Bonnet-Serrano, Hervé Lefebvre, Marie-Laure Raffin-Sanson, Nicolas Chevalier, Philippe Touraine, Christel Jublanc, Camille Vatier, Gérald Raverot, Magalie Haissaguerre, Luigi Maione, Matthias Kroiss, Martin Fassnacht, Sophie Christin-Maitre, Eric Pasmant, Françoise Borson-Chazot, Antoine Tabarin, Marie-Christine Vantyghem, Martin Reincke, Peter Kamenicky, Marie-Odile North, Jérôme Bertherat, Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Cancer et génome: Bioinformatique, biostatistiques et épidémiologie d'un système complexe, Mines Paris - PSL (École nationale supérieure des mines de Paris), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Curie [Paris]-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], CHU Lille, Recherche translationnelle sur le diabète - U 1190 (RTD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU Rouen, Normandie Université (NU), Hôpital Ambroise Paré [AP-HP], Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Hospices Civils de Lyon (HCL), Hôpital Haut-Lévêque - CHU de Bordeaux (Centre médico chirurgical Magellan), Physiologie et physiopathologie endocriniennes (PHYSENDO), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), University Hospital of Würzburg, Klinikum der Universität [München], CHU Saint-Antoine [AP-HP], L B is recipient of research fellowships from the Cancer Research for Personalized Medicine (CARPEM) and the Fondation ARC pour la Recherche contre le Cancer, J B laboratory is supported by the Agence Nationale pour la Recherche grant ANR-18-CE14-0008-01 and the Fondation pour la Recherche Médicale (EQU201903007854). P T, C J, M F, S C M, F B C, M R, P C and J B clinical departments are part the European Reference Network on Rare Endocrine Conditions (Endo-ERN) – Project ID No 739572, and ANR-18-CE14-0008,STEROMICS,Steroïdogénomique de l'hypersécrétion des stéroïdes surrénaliens(2018)
- Subjects
Armadillo Domain Proteins ,Hyperplasia ,Hydrocortisone ,Endocrinology, Diabetes and Metabolism ,[SDV]Life Sciences [q-bio] ,71 ARMC5 ,General Medicine ,genetic screening ,PBMAH ,Endocrinology ,Primary Bilateral Macronodular Adrenal Hyperplasia ,adrenal tumors ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,Adrenal Glands ,Humans ,Cushing syndrome ,tumor suppressor gene ,Retrospective Studies - Abstract
Objective Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a heterogeneous disease characterized by adrenal macronodules and variable levels of cortisol excess, with not clearly established clinical diagnostic criteria. It can be caused by ARMC5 germline pathogenic variants. In this study, we aimed to identify predictive criteria for ARMC5 variants. Methods We included 352 consecutive index patients from 12 European centers, sequenced for germline ARMC5 alteration. Clinical, biological and imaging data were collected retrospectively. Results 52 patients (14.8%) carried ARMC5 germline pathogenic variants and showed a more distinct phenotype than non-mutated patients for cortisol excess (24-h urinary free cortisol 2.32 vs 1.11-fold ULN, respectively, P < 0.001) and adrenal morphology (maximal adrenal diameter 104 vs 83 mm, respectively, P < 0.001) and were more often surgically or medically treated (67.9 vs 36.8%, respectively, P < 0.001). ARMC5-mutated patients showed a constant, bilateral adrenal involvement and at least a possible autonomous cortisol secretion (defined by a plasma cortisol after 1 mg dexamethasone suppression above 50 nmol/L), while these criteria were not systematic in WT patients (78.3%). The association of these two criteria holds a 100% sensitivity and a 100% negative predictive value for ARMC5 pathogenic variant. Conclusion We report the largest series of index patients investigated for ARMC5 and confirm that ARMC5 pathogenic variants are associated with a more severe phenotype in most cases. To minimize negative ARMC5 screening, genotyping should be limited to clear bilateral adrenal involvement and autonomous cortisol secretion, with an optimum sensitivity for routine clinical practice. These findings will also help to better define PBMAH diagnostic criteria.
- Published
- 2023
- Full Text
- View/download PDF
10. Reply of the Authors: Genetics of primary ovarian insufficiency: a careful step-by-step approach based on solid foundations to bring new knowledge
- Author
-
Sophie, Christin-Maitre, Jean-Pierre, Siffroi, Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], UF de Génétique chromosomique [CHU Trousseau], CHU Trousseau [APHP], and Couvet, Sandrine
- Subjects
[SDV] Life Sciences [q-bio] ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,Reproductive Medicine ,[SDV]Life Sciences [q-bio] ,Humans ,Obstetrics and Gynecology ,Female ,[SDV.GEN] Life Sciences [q-bio]/Genetics ,Primary Ovarian Insufficiency - Abstract
International audience; No abstract available
- Published
- 2022
- Full Text
- View/download PDF
11. Premature Ovarian Insufficiency in CLPB Deficiency: Transcriptomic, Proteomic and Phenotypic Insights
- Author
-
Elena J Tucker, Megan J Baker, Daniella H Hock, Julia T Warren, Sylvie Jaillard, Katrina M Bell, Rajini Sreenivasan, Shabnam Bakhshalizadeh, Chloe A Hanna, Nikeisha J Caruana, Saskia B Wortmann, Shamima Rahman, Robert D S Pitceathly, Jean Donadieu, Aurelia Alimi, Vincent Launay, Paul Coppo, Sophie Christin-Maitre, Gorjana Robevska, Jocelyn van den Bergen, Brianna L Kline, Katie L Ayers, Phoebe N Stewart, David A Stroud, Diana Stojanovski, Andrew H Sinclair, University of Melbourne, Murdoch Children's Research Institute (MCRI), Durham University, Washington University School of Medicine [Saint Louis, MO], Service de Cytogénétique et de Biologie Cellulaire, Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Royal Children's Hospital Melbourne, Victoria University [Melbourne], Paracelsus Medizinische Privatuniversität = Paracelsus Medical University (PMU), Amalia Children’s Hospital [Nijmegen, The Netherlands], Great Ormond Street Hospital for Children NHS Foundation Trust [London, UK] (GOSHC), UCL Institute of Neurology, Queen Square [London], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU de Saint-Brieuc, CHU Saint-Antoine [AP-HP], Sorbonne Université (SU), Royal Hobart Hospital, and This work was supported by an National Health and Medical Research Council (NHMRC) program grant (1074258 toA.H.S.), NHMRC grant (1140906 to D.A.S.), NHMRC fellowships (1054432 to E.J.T., 1126995 to R.S., 2009732 to D.A.S., 1062854 to A.H.S.), a Suzi Carp postdoctoral scholarship (to E.J.T.), a CHU Rennes grant (Appel à Projets Innovations 2019 to S.J.), an Australian Government Research Training Program scholarship (to M.J.B.), the Australian Mito Foundation for provision of instrumentation, incubator grants (to E.J.T. and D.S.), a Booster grant (to D.S.) and PhD Top-up scholarships (to M.J.B. and D.H.H.), and a Medical Research Council (UK) Clinician Scientist Fellowship (MR/S002065/1 to R.D.S.P.). S.B.W. was funded by ERAPERMED2019-310—Personalized Mitochondrial Medicine (PerMiM): Optimizing diagnostics and treatment for patients with mitochondrial diseases (FWF 4704-B).
- Subjects
Proteomics ,premature ovarian insufficiency ,Neutropenia ,[SDV]Life Sciences [q-bio] ,Endocrinology, Diabetes and Metabolism ,primary mitochondrial disease ,Biochemistry (medical) ,Clinical Biochemistry ,Menopause, Premature ,Metabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6] ,Endopeptidase Clp ,Primary Ovarian Insufficiency ,Biochemistry ,Cataract ,mitochondria ,Endocrinology ,Phenotype ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,CLPB ,Humans ,genetics ,Female ,infertility ,Transcriptome - Abstract
Context Premature ovarian insufficiency (POI) is a common form of female infertility that usually presents as an isolated condition but can be part of various genetic syndromes. Early diagnosis and treatment of POI can minimize comorbidity and improve health outcomes. Objective We aimed to determine the genetic cause of syndromic POI, intellectual disability, neutropenia, and cataracts. Methods We performed whole-exome sequencing (WES) followed by functional validation via RT-PCR, RNAseq, and quantitative proteomics, as well as clinical update of previously reported patients with variants in the caseinolytic peptidase B (CLPB) gene. Results We identified causative variants in CLPB, encoding a mitochondrial disaggregase. Variants in this gene are known to cause an autosomal recessive syndrome involving 3-methylglutaconic aciduria, neurological dysfunction, cataracts, and neutropenia that is often fatal in childhood; however, there is likely a reporting bias toward severe cases. Using RNAseq and quantitative proteomics we validated causation and gained insight into genotype:phenotype correlation. Clinical follow-up of patients with CLPB deficiency who survived to adulthood identified POI and infertility as a common postpubertal ailment. Conclusion A novel splicing variant is associated with CLPB deficiency in an individual who survived to adulthood. POI is a common feature of postpubertal female individuals with CLPB deficiency. Patients with CLPB deficiency should be referred to pediatric gynecologists/endocrinologists for prompt POI diagnosis and hormone replacement therapy to minimize associated comorbidities.
- Published
- 2022
- Full Text
- View/download PDF
12. Prevalence of lifetime eating disorders in infertile women seeking pregnancy with pulsatile gonadotropin-releasing hormone therapy
- Author
-
Simone Perdigao-Cotta, Alexandra Pham-Scottez, Irema Barbosa-Magalhaes, Chrysoula Papastathi, Isabelle Nicolas, Claire Lamas, Sophie Christin-Maitre, Julie Galey, Maurice Corcos, and Marie de Crecy
- Subjects
Infertility ,050103 clinical psychology ,medicine.medical_specialty ,030309 nutrition & dietetics ,medicine.medical_treatment ,media_common.quotation_subject ,Fertility ,Anorexia nervosa ,Feeding and Eating Disorders ,Gonadotropin-Releasing Hormone ,03 medical and health sciences ,Pregnancy ,Prevalence ,medicine ,Humans ,0501 psychology and cognitive sciences ,Amenorrhea ,media_common ,0303 health sciences ,Assisted reproductive technology ,business.industry ,Obstetrics ,05 social sciences ,medicine.disease ,CIDI ,Psychiatry and Mental health ,Clinical Psychology ,Eating disorders ,Cohort ,Female ,Observational study ,France ,business ,Infertility, Female - Abstract
Relationships between weight and fertility are well known. The aim of this study is to assess the prevalence of lifetime eating disorder (ED) in a sample of infertile women seeking a specific infertility treatment, pulsatile gonadotropin-releasing hormone (pGnRH) treatment, and to compare it to the prevalence of lifetime ED in a sample of infertile women seeking other types of assisted reproductive technology (ART) treatments.Non-randomized, observational study including infertile female patients. Two-group design including consecutive women treated with GnRH pump (pGnRH) or with other types of ART.Multi-centric infertility centers, France METHODS: Twenty one consecutive women treated with pGnRH treatment were compared to 21 consecutive women receiving other types of infertility treatment. Diagnosis of ED was based on DSM-IV and the Composite International Diagnostic Interview (CIDI).Twenty patients (95.2%) from the sample of women treated with pulsatile GnRH treatment and 5 patients (23.8%) from the patients receiving other types of infertility treatment met the criteria of lifetime ED diagnosis (p 0.000).This study highlights the fact that the prevalence of ED is considerably higher in women receiving GnRH pulsatile treatment, when compared to women receiving other kinds of infertility treatment. In our study population ED were under-diagnosed, particularly in women receiving pulsatile GnRH treatment. Fertility clinicians should use reliable diagnostic tools to identify promptly ED in women presenting with hypothalamic amenorrhea and difficulties in conceiving. Level III: Evidence obtained from well-designed cohort or case-control analytic studies.
- Published
- 2020
- Full Text
- View/download PDF
13. [Worldwide contraception]
- Author
-
Sophie, Christin-Maitre
- Subjects
Adult ,Male ,Young Adult ,Contraception ,Adolescent ,Contraceptive Agents ,Pregnancy ,Family Planning Services ,Sterilization, Reproductive ,Humans ,Female ,Middle Aged - Abstract
The latest statistics concerning contraceptive use in the world have been published in 2019 by the United Nations. Among the 1.9 billion of women of reproductive age (15-49 years), 1.1 billion have a need for family planning. Among them, 190 millions are not using any contraception, although they wanted to avoid a pregnancy. There is a significant discrepancy among continents concerning the percentage of contraceptive use and the distribution of the different types of contraception. Female sterilization is the most widespread method of contraception since it represents 24% of all contraception methods used. Male condoms is used by 21% of couples. Thus, progress is still needed to disseminate effective, well tolerated and potentially reversible methods of contraception. Education of females, couples, medical and paramedical staff is one of the priority targets to improve contraception throughout the world.La contraception à travers le monde.Les dernières données concernant la contraception à travers le monde ont été publiées en 2019 par l’Organisation des Nations unies (ONU). Parmi les 1,9 milliard de femmes en âge de procréer (entre 15 et 49 ans), 1,1 milliard souhaitaient une contraception. Pourtant, 10 % d’entre elles n’utilisaient pas de méthode contraceptive, essentiellement en raison d’un manque d’accès à ces méthodes. Selon les continents, une grande disparité est observée dans l’utilisation des différentes méthodes contraceptives. La stérilisation féminine, ou contraception définitive, reste cependant la méthode majoritairement utilisée puisqu’elle représente 24 % des contraceptions. Des progrès sont nécessaires, en particulier dans l’éducation, pour améliorer la diffusion d’autres méthodes également efficaces, qui sont bien tolérées et possiblement réversibles.
- Published
- 2022
14. Aortic Tissue Analysis in Turner Syndrome
- Author
-
Bruno Donadille, Alexander Valent, Kisaki Amemiya, Nicolas Rive le Gouard, Laurence Iserin, Paul Achouh, Tatiana Lecot-Connan, Patrick Bruneval, Jean-Pierre Siffroi, and Sophie Christin-Maitre
- Subjects
Aortic Dissection ,Hypertension ,Humans ,Turner Syndrome ,Cardiology and Cardiovascular Medicine - Published
- 2022
15. Whole exome sequencing in a cohort of familial premature ovarian insufficiency cases reveals a broad array of pathogenic or likely pathogenic variants in 50% of families
- Author
-
Alexandre Rouen, Eli Rogers, Véronique Kerlan, Brigitte Delemer, Sophie Catteau-Jonard, Yves Reznik, Anne Gompel, Isabelle Cedrin, Anne-Marie Guedj, Virginie Grouthier, Thierry Brue, Catherine Pienkowski, Anne Bachelot, Sandra Chantot-Bastaraud, Alexandra Rousseau, Tabassome Simon, Esther Kott, Jean-Pierre Siffroi, Philippe Touraine, Sophie Christin-Maitre, Maladies génétiques d'expression pédiatrique (U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Universitaire de Reims (CHU Reims), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Hopital port Royal, Partenaires INRAE, Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Marseille Maladies Rares (MarMaRa), Aix Marseille Université (AMU), Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM], CHU Saint-Antoine [AP-HP], and Programme Hospitalier de Recherche Clinique AOM08084, NI07022 FAMIOP
- Subjects
premature ovarian insufficiency ,Genes in POI ,[SDV]Life Sciences [q-bio] ,Menopause, Premature ,Obstetrics and Gynecology ,Primary Ovarian Insufficiency ,hypergonadotropic hypogonadism ,whole exome sequencing ,Cohort Studies ,Fragile X Mental Retardation Protein ,Cross-Sectional Studies ,primary amenorrhea ,Reproductive Medicine ,Exome Sequencing ,Humans ,Female - Abstract
International audience; Objective: To study the diagnostic yield, including variants in genes yet to be incriminated, of whole exome sequencing (WES) in familial cases of premature ovarian insufficiency (POI). Design: Cross-sectional study. Setting: Endocrinology and reproductive medicine teaching hospital departments. Patients: Familial POI cases were recruited as part of a nationwide multicentric cohort. A total of 36 index cases in 36 different families were studied. Fifty-two relatives were available, including 25 with POI and 27 affected who were nonaffected. Karyotype analysis, FMR1 screening, single nucleotide polymorphism array analysis, and WES were performed in all subjects. Interventions: None. Main Outcome Measures: The primary outcome was a molecular etiology, as diagnosed by karyotype, FMR1 screening, single nucleotide polymorphism array, and WES. Results: A likely molecular etiology (pathogenic or likely pathogenic variant) was identified in 18 of 36 index cases (50% diagnostic yield). In 12 families, we found a pathogenic or likely pathogenic variant in a gene previously incriminated in POI, and in 6 families, we found a pathogenic or likely pathogenic variant in new candidate genes. Most of the variants identified were located in genes involved in cell division and meiosis (n = 11) or DNA repair (n = 4). Conclusions: The genetic etiologic diagnosis in POI allows for genetic familial counseling, anticipated pregnancy planning, and ovarian tissue preservation or oocyte preservation. Identifying new genes may lead to future development of therapeutics in reproduction based on disrupted molecular pathways. Clinical Trial Registration Number: NCT 01177891. ((C) 2021 by American Society for Reproductive Medicine.) El resumen esta disponible en Espanol al final del articulo.
- Published
- 2022
- Full Text
- View/download PDF
16. Role of 68Ga-DOTATOC PET/CT in Insulinoma According to 3 Different Contexts: A Retrospective Study
- Author
-
Pierre-Louis Moreau, Cyrielle Aveline, Sophie Christin-Maitre, Philippe Chanson, Olivier Dubreuil, Timofei Rusu, and Françoise Montravers
- Subjects
Adult ,Pancreatic Neoplasms ,Positron Emission Tomography Computed Tomography ,Organometallic Compounds ,Humans ,Radiology, Nuclear Medicine and imaging ,Insulinoma ,General Medicine ,Octreotide ,Retrospective Studies - Abstract
The aim of this study was to assess the performance of 68Ga-DOTATOC PET/CT in the detection and extension of insulinomas according to 3 different contexts: sporadic benign, sporadic metastatic, and multiple endocrine neoplasia type 1 (MEN1).The data of 71 adult patients who underwent 68Ga-DOTATOC PET/CT for suspected or confirmed sporadic insulinoma, suspicion of insulinoma in the context of MEN1, follow-up of metastatic insulinoma, or suspicion of recurrence of insulinoma were retrospectively analyzed. Pathological examination or strong clinical and biological findings were used as standards of truth.For the assessment of a confirmed sporadic insulinoma in 17 patients, the sensitivity of SR-PET was 75%, including 2 patients for whom metastatic lesions had been revealed by SR-PET. For 35 patients with a suspicion of insulinoma, the sensitivity was 39%. In 10 patients followed up for metastatic insulinoma, the sensitivity was 100%. For 5 patients with a history of MEN1, interpretation of SR-PET was difficult, as 3 of them presented with multiple pancreatic uptake foci. The global sensitivity of SR-PET in all insulinomas excluding those with a MEN1 story was 64% (100% for metastatic insulinomas, 62% for benign insulinomas), with a specificity of 89%.68Ga-DOTATOC PET/CT is a useful examination tool for the assessment of insulinomas in selected contexts, with very high performance for the detection and extension workup of metastatic insulinomas and high specificity for the detection of sporadic benign insulinomas. The examination should be completed with GLP-1 receptor PET when it is negative or in a MEN1 context.
- Published
- 2022
17. Turner syndrome: French National Diagnosis and Care Protocol (NDCP; National Diagnosis and Care Protocol)
- Author
-
Elodie Fiot, Bertille Alauze, Bruno Donadille, Dinane Samara-Boustani, Muriel Houang, Gianpaolo De Filippo, Anne Bachelot, Clemence Delcour, Constance Beyler, Emilie Bois, Emmanuelle Bourrat, Emmanuel Bui Quoc, Nathalie Bourcigaux, Catherine Chaussain, Ariel Cohen, Martine Cohen-Solal, Sabrina Da Costa, Claire Dossier, Stephane Ederhy, Monique Elmaleh, Laurence Iserin, Hélène Lengliné, Armelle Poujol-Robert, Dominique Roulot, Jerome Viala, Frederique Albarel, Elise Bismuth, Valérie Bernard, Claire Bouvattier, Aude Brac, Patricia Bretones, Nathalie Chabbert-Buffet, Philippe Chanson, Regis Coutant, Marguerite de Warren, Béatrice Demaret, Lise Duranteau, Florence Eustache, Lydie Gautheret, Georges Gelwane, Claire Gourbesville, Mickaël Grynberg, Karinne Gueniche, Carina Jorgensen, Veronique Kerlan, Charlotte Lebrun, Christine Lefevre, Françoise Lorenzini, Sylvie Manouvrier, Catherine Pienkowski, Rachel Reynaud, Yves Reznik, Jean-Pierre Siffroi, Anne-Claude Tabet, Maithé Tauber, Vanessa Vautier, Igor Tauveron, Sebastien Wambre, Delphine Zenaty, Irène Netchine, Michel Polak, Philippe Touraine, Jean-Claude Carel, Sophie Christin-Maitre, Juliane Léger, Centre de Référence des Maladies Endocriniennes Rares de la Croissance [APHP Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Cité (UPCité), Maladies neurodéveloppementales et neurovasculaires (NeuroDiderot (UMR_S_1141 / U1141)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'endocrinologie, gynécologie et diabétologie pédiatriques [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Trousseau [APHP], CHU Pitié-Salpêtrière [AP-HP], Département d'obstétrique et de gynécologie [Hôpital Robert Debré], Université Paris Diderot - Paris 7 (UPD7)-AP-HP Hôpital universitaire Robert-Debré [Paris], AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Charles Foix [AP-HP], Service de Rhumatologie [CHU Lariboisière], Hôpital Lariboisière-Fernand-Widal [APHP], Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Hôpital Avicenne [AP-HP], Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM], Aix Marseille Université (AMU), CHU de Bordeaux Pellegrin [Bordeaux], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Hospices Civils de Lyon (HCL), CHU Tenon [AP-HP], Endocrinologie pédiatrique[CHU Angers], Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Hôpital Jean Verdier [AP-HP], Service Endocrinologie - Diabétologie [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), AP-HP - Hôpital Antoine Béclère [Clamart], Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Jeanne de Flandre [Lille], Service de pédiatrie multidisciplinaire [Hôpital de la Timone Enfants - APHM], Hôpital de la Timone [CHU - APHM] (TIMONE), CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Maladies génétiques d'expression pédiatrique (U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Département de génétique [Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP Hôpital universitaire Robert-Debré [Paris], CHU Clermont-Ferrand, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), and Ministère de la Santé
- Subjects
Adult ,Chromosomes, Human, X ,Karyotype ,Turner’s syndrome ,Turner Syndrome ,General Medicine ,Recommendation ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,Adulthood ,Childhood ,Management ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,Diabetes Mellitus, Type 2 ,Karyotyping ,Diagnosis ,Humans ,Pharmacology (medical) ,Female ,Genetics (clinical) - Abstract
Turner syndrome (TS; ORPHA 881) is a rare condition in which all or part of one X chromosome is absent from some or all cells. It affects approximately one in every 1/2500 liveborn girls. The most frequently observed karyotypes are 45,X (40–50%) and the 45,X/46,XX mosaic karyotype (15–25%). Karyotypes with an X isochromosome (45,X/46,isoXq or 45,X/46,isoXp), a Y chromosome, X ring chromosome or deletions of the X chromosome are less frequent. The objective of the French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins) is to provide health professionals with information about the optimal management and care for patients, based on a critical literature review and multidisciplinary expert consensus. The PNDS, written by members of the French National Reference Center for Rare Growth and Developmental Endocrine disorders, is available from the French Health Authority website. Turner Syndrome is associated with several phenotypic conditions and a higher risk of comorbidity. The most frequently reported features are growth retardation with short adult stature and gonadal dysgenesis. TS may be associated with various congenital (heart and kidney) or acquired diseases (autoimmune thyroid disease, celiac disease, hearing loss, overweight/obesity, glucose intolerance/type 2 diabetes, dyslipidemia, cardiovascular complications and liver dysfunction). Most of the clinical traits of TS are due to the haploinsufficiency of various genes on the X chromosome, particularly those in the pseudoautosomal regions (PAR 1 and PAR 2), which normally escape the physiological process of X inactivation, although other regions may also be implicated. The management of patients with TS requires collaboration between several healthcare providers. The attending physician, in collaboration with the national care network, will ensure that the patient receives optimal care through regular follow-up and screening. The various elements of this PNDS are designed to provide such support.
- Published
- 2022
- Full Text
- View/download PDF
18. Multiple endocrine neoplasia type 1 or 4: detection of hyperfunctioning parathyroid glands with 18F-fluorocholine PET/CT. Illustrative cases and pitfalls
- Author
-
Jean-Noël TALBOT, Jules ZHANG-YIN, Khadoun KERROU, Cyrielle AVELINE, Benedicte VAGNE, Ophélie BÉLISSANT, Marc TASSART, Sophie PÉRIÉ, Phillipe BOUCHARD, Sophie CHRISTIN-MAITRE, Fabrice MÉNÉGAUX, Lionel GROUSSIN, Sébastien GAUJOUX, Soňa BALOGOVÁ, and Françoise MONTRAVERS
- Subjects
Parathyroid Glands ,Technetium Tc 99m Sestamibi ,Positron Emission Tomography Computed Tomography ,Multiple Endocrine Neoplasia Type 1 ,Humans ,Radiology, Nuclear Medicine and imaging ,Hyperparathyroidism, Primary ,Choline ,Retrospective Studies - Published
- 2022
19. Pre-pregnancy counselling in patients with Turner syndrome: A multidisciplinary approach
- Author
-
Bruno Donadille, Clément Cholet, Laurence Iserin, Paul Achouh, Anne Bachelot, Nathalie Bourcigaux, Emmanuelle Mathieu-d’Argent, Stéphane Ederhy, and Sophie Christin-Maitre
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Published
- 2022
- Full Text
- View/download PDF
20. Hormones and fertility
- Author
-
Agnès Linglart, Sophie Christin-Maitre, Dominique Maiter, and Philippe Touraine
- Subjects
Fertility ,Endocrinology ,Research Design ,Endocrinology, Diabetes and Metabolism ,Humans ,General Medicine ,Hormones - Published
- 2022
- Full Text
- View/download PDF
21. Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases
- Author
-
Iulia Potorac, Jean-François Bonneville, Adrian F Daly, Wouter de Herder, Patricia Fainstein-Day, Philippe Chanson, Marta Korbonits, Fernando Cordido, Elisa Baranski Lamback, Mohamed Abid, Véronique Raverot, Gerald Raverot, Emma Anda Apiñániz, Philippe Caron, Helene Du Boullay, Martin Bidlingmaier, Marek Bolanowski, Marie Laloi-Michelin, Francoise Borson-Chazot, Olivier Chabre, Sophie Christin-Maitre, Claire Briet, Gonzalo Diaz-Soto, Fabrice Bonneville, Frederic Castinetti, Mônica R Gadelha, Nathalie Oliveira Santana, Maria Stelmachowska-Banaś, Tomas Gudbjartsson, Roció Villar-Taibo, Taiba Zornitzki, Luaba Tshibanda, Patrick Petrossians, Albert Beckers, Université de Liège, Centre Hospitalier Universitaire de Liège (CHU-Liège), Erasmus University Medical Center [Rotterdam] (Erasmus MC), Hospital Italiano - BUENOS AIRES (Hop It - BUENOS AIRES), AP-HP. Université Paris Saclay, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Physiologie et physiopathologie endocriniennes (PHYSENDO), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Queen Mary University of London (QMUL), A Coruña University Hospital [La Corogne, Espagne], Universidade Federal do Rio de Janeiro (UFRJ), Hedi Chaker Hospital [Sfax], Groupement Hospitalier Lyon-Est (GHE), Hospices Civils de Lyon (HCL), Navarra Hospital Complex - Complejo Hospitalario de Navarra [Pamplona, Spain] (CHN), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Centre Hospitalier Métropole Savoie [Chambéry], Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München (LMU), Ludwig-Maximilians University [Munich] (LMU), Wrocław Medical University, Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hospital Clinico Universitario de Valladolid [Castilla y León, Spain] (HCUV), Service Neuroradiologie Diagnostique et Thérapeutique [CHU Toulouse], Pôle imagerie médicale [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Aix Marseille Université (AMU), Universidade de São Paulo = University of São Paulo (USP), Centre of Postgraduate Medical Education [Warsaw, Poland] (CPME), Landspitali National University Hospital of Iceland, Complejo Hospitalario Universitario de Santiago de Compostela [Saint-Jacques-de-Compostelle, Espagne] (CHUS), The Hebrew University Hadassah Medical School, Fonds d’Investissment pour la Recherche (FIRS) of the Centre Hospitalier Universitaire de Liege (Grant Number 2018-2020), and Internal Medicine
- Subjects
T2-hypointense ,Endocrinology, Diabetes and Metabolism ,ectopic ,Biochemistry (medical) ,Clinical Biochemistry ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,Growth Hormone-Releasing Hormone ,pituitary ,Biochemistry ,Magnetic Resonance Imaging ,Neuroendocrine Tumors ,Endocrinology ,GHRH ,SDG 3 - Good Health and Well-being ,Pituitary Gland ,Acromegaly ,Humans ,neuroendocrine tumor ,MRI ,Retrospective Studies - Abstract
Context Ectopic acromegaly is a consequence of rare neuroendocrine tumors (NETs) that secrete GHRH. This abnormal GHRH secretion drives GH and IGF-1 excess, with a clinical presentation similar to classical pituitary acromegaly. Identifying the underlying cause for the GH hypersecretion in the setting of ectopic GHRH excess is, however, essential for proper management both of acromegaly and the NET. Owing to the rarity of NETs, the imaging characteristics of the pituitary in ectopic acromegaly have not been analyzed in depth in a large series. Objective Characterize pituitary magnetic resonance imaging (MRI) features at baseline and after NET treatment in patients with ectopic acromegaly. Design Multicenter, international, retrospective. Setting Tertiary referral pituitary centers. Patients Thirty ectopic acromegaly patients having GHRH hypersecretion. Intervention None. Main outcome measure MRI characteristics of pituitary gland, particularly T2-weighted signal. Results In 30 patients with ectopic GHRH-induced acromegaly, we found that most patients had hyperplastic pituitaries. Hyperplasia was usually moderate but was occasionally subtle, with only small volume increases compared with normal ranges for age and sex. T2-weighted signal was hypointense in most patients, especially in those with hyperplastic pituitaries. After treatment of the NET, pituitary size diminished and T2-weighted signal tended to normalize. Conclusions This comprehensive study of pituitary MRI characteristics in ectopic acromegaly underlines the utility of performing T2-weighted sequences in the MRI evaluation of patients with acromegaly as an additional tool that can help to establish the correct diagnosis.
- Published
- 2021
- Full Text
- View/download PDF
22. Author response for 'Influenza vaccination and prognosis of COVID ‐19 in hospitalized patients with diabetes: Results from the CORONADO study'
- Author
-
null A Diallo, null M Pichelin, null M Wargny, null P Gourdy, null JB Bonnet, null S Hadjadj, null B Cariou, null A Sultan, null F Galtier, null Matthieu Wargny, null Pascale Mahot, null Bertrand Cariou, null Samy Hadjadj, null Matthieu Pichelin, null Anne‐Laure Fournier‐Guilloux, null Nicolas Mauduit, null Edith Bigot‐Corbel, null Anne‐Sophie Boureau, null Laure Dekcer, null Audrey Ernould, null Claire Primot, null Anne Seguin, null Marielle Joliveau, null Sonia Pouvreau, null Chloé FOURNIER, null Jeremy Thureau, null Edith Fonteneau, null Pamela Hublain, null Chu Nantes, null Carole Agasse, null Mathilde DE Kergaradec, null Vincent Minville, null Fanny Vardon‐Bounes, null Guillaume Martin‐Blondel, null Pierre Gourdy, null Blandine Tramunt, null Marie‐Christine Turnin, null Hélène Hanaire, null Jean‐Michel Mansuy, null Didier Fabre, null Marie‐Blanche Arhainx, null Laurent Cazals, null Laure Combes, null Emmanuelle Lami, null Mallory Cianferani, null Bruno Megarbane, null Pierre Leroy, null Jean‐François Gautier, null Tiphaine Vidal‐Trecan, null Jean‐Pierre Riveline, null Jean‐Louis Laplanche, null Stéphane Mouly, null Louis Potier, null Ronan Roussel, null Malak Taher, null Yawa Abouleka, null Fetta Yaker, null Aurelie Carlier, null Anne Boutten, null Marilyne Hallot‐Feron, null Fadila Mourah, null Charles Thivolet, null Emilie Blond, null Muriel Rolland, null Josep Verdecho Mendez, null Marine Alexandre, null Julien Pottecher, null Emilie Richer, null Laurent Meyer, null Florina Luca, null Jean‐Marc Lessinger, null Thibault Bahougne, null Bruno Guerci, null Lisa Ludwig, null Siham Benzirar, null Catherine Malaplate, null Thierry Matton, null Julien Poissy, null Karine Faure, null Pierre Fontaine, null Florence Baudoux, null Anne Vambergue, null Jean David Pekar, null Marc Lambert, null Cécile Yelnik, null Amélie Bruandet, null Laurent Petit, null Didier Neau, null Vincent Rigalleau, null Annie Berard, null Amandine Galioot, null Remy Coudroy, null Arnaud Thille, null René Robert, null France Roblot‐Cazenave, null Blandine Rammaert, null Pierre Jean Saulnier, null Xavier Piguel, null Nesrine Benhenda, null Camille Husson, null Celine Olivier, null Florence Torremocha, null Mathilde Fraty, null Marie Flamen d'assigny, null Aurelie Miot, null Valentin Bossard, null Kada Klouche, null Alain Makinson, null Ariane Sultan, null Jean‐Baptiste Bonnet, null Vincent Foulongne, null Florence Galtier, null Cécile Aubron, null Séverine Ansart, null Véronique Kerlan, null Pascale Quiniou, null Jean‐Luc Carre, null Stéphane Quesnot, null Bruno Laviolle, null Carole Schwebel, null Olivier Epaulard, null Pierre‐Yves Benhamou, null Cécile Betry, null Anne‐Laure Borel, null Sandrine Lablanche, null Dorra Guergour, null Catherine Duclos, null Emmanuel Cosson, null Erwan Guyot, null Aurore Deniau, null Phucthutrang Nguyen, null Yves Reznik, null Michael Joubert, null Stéphane Allouche, null Lydia Guittet, null Steven Grange, null Manuel Etienne, null Gaëtan Prévost, null Valéry Brunel, null Jean‐Christophe Lagier, null Didier Raoult, null Anne Dutour, null Bénédicte Gaborit, null Sandrine Boulllu, null Patrice Darmon, null Adèle Lasbleiz, null Mathieu Cerino, null Fanny Romain, null Marie Houssays, null Jean Pierre Quenot, null Lionel Piroth, null Bruno Vergès, null Laurence Duvillard, null Bernard Bonnotte, null Alain Mercat, null Vincent Dubee, null Ingrid Allix, null Patrice Rodien, null Robin Dhersin, null Maylis Lebeault, null Wojciech Trzepizur, null Jocelyne Loison, null Antoine Brangier, null Pierre Asfar, null Pascal Reynier, null Françoise Larcher, null Françoise Joubaud, null Marie‐Rita Andreu, null Geoffrey Urbanski, null Laurent Hubert, null Cedric Annweiler, null Jean Dellamonica, null Johan Courjon, null Nicolas Chevalier, null Giulia Chinetti, null Magda Chafai, null Bruno Mourvillier, null Firouze Bani‐Sadr, null Sarra Barraud, null Brigitte Delemer, null Philippe Gillery, null Pascale Labedade, null Amélie Chabrol, null Alfred Penfornis, null Catherine Petit, null Coralie Amadou, null Maxime Adler, null Clément Dubost, null Pierre‐Louis Conan, null Lyse Bordier, null Franck Ceppa, null Cyril Garcia, null Mathilde Sollier, null Olivier Dupuy, null Sophie Laplance, null Olivier Billuart, null Marie Joseph Aroulanda, null Frédérique Olivier, null Florence Ayon, null Nathalie Wilhelm, null Loic Epelboin, null Nadia Sabbah, null Aurelie Charpin, null Pierre Squara, null Olivier Belliard, null Claude Dubois, null Michel Marre, null Johann Auchabie, null Roxane Courtois, null Thierry Duriez, null Tiphaine Mergey, null Laura Vallee, null Laetitia Seguin, null Abdallah Al‐Salameh, null Jean‐Philippe Lanoix, null Sandrine Soriot‐Thomas, null Anne‐Marie Bourgeois‐Descouls, null Rachel Desailloud, null Natacha Germain, null Bogdan Galusca, null Gwenaelle Belleton, null Nesrine Marouani, null Delia Palaghiu, null Amira Hammour, null Fernando Berdaguer, null Thimothée Klopfenstein, null Hajer Zayet, null Patrice Winiszewski, null Marie Zanusso, null Pauline Garnier, null Ingrid Julier, null Karim Hamzaoui, null Sophie Marty‐Gres, null Tarik Sadki, null Lucile Cadot, null Jean‐Louis Dubost, null Céline Gonfroy, null Catherine Campinos, null Pascale Martres, null Marie Pierre Coulhon, null Nicolas Allou, null Marwa Bachir, null Stella Hoang, null Candice Kembellec, null Olivia Suply, null Fatima Kharcha, null Anne‐Claire Devouge, null Anna Flaus‐Furmanuk, null Isabelle Madeline, null Vincent Ehinger, null Sophie Bastard, null Loic Raffray, null Frederic Renou, null Aude Bojarski, null Caroline Paul, null Karine Borsu, null Angelique Gorlin, null Servane Bernardo, null Carole Truong Ut, null Stephane Renaud, null Antoine Vignoles, null Emilie Foch, null Laurie Masse, null Hubert Grand, null Helene Ferrand, null Christelle Raffaitin‐Cardin, null Hadjer Zellagui, null Celine Castang‐Brachet, null Frederique Boury, null Ana Alvarez Tena, null Isabelle Moura, null Pierre Kalfon, null Juliana Darasteanu, null Arnaud Monier, null Pascal Foucault, null Alexandra Depuille, null Stéphanie Laugier‐Robiolle, null Patrick Caneiro, null Maud Basso, null Etienne Larger, null Samir Bouam, null Wahiba Benzenati, null Leila Ait Bachir, null Camille Cussac Pillegand, null Marc Vasse, null Christophe Michard, null Nathanaëlle Montanier, null Luc Millot, null Françoise Crepet, null Danielle Ratsimba, null Kevin Bouiller, null Sophie Borot, null Isabelle Bruckert, null Annie Clergeot, null Franck Schillo, null Dorothée Vignes, null Muriel Bourgeon‐Ghittori, null Hamoud Lachgar, null Claire Lambert DE Cursay, null Stéphane Levante, null Jean Charles Auregan, null Antoine Merlet, null Cécile Zaragoza, null Gwénaëlle Arnault, null Anne‐Gaëlle Loupp, null Olivier Lesieur, null Mariam Roncato‐Saberan, null Didier Gouet, null Romain Lemarie, null Hong_an Allano, null Emmanuel Vivier, null Caroline Pariset, null Cédric Luyton, null Lucien Marchand, null Fanny Doroszewski, null Matthieu Pecquet, null Laurent Perard, null Sylvie Vuillermoz‐Blas, null Nicolas Kacki, null Patricia Charrier, null Amélie Ducet‐Boiffard, null Françoise Desroys Roure, null Olivier Bourron, null Dominique Bonnefont‐Rousselot, null Suzanne Laroche, null Franck Phan, null Agnès Hartemann, null Cyrielle Caussy, null Emmanuel Disse, null Claude Guerin, null Thomas Perpoint, null Philippe Moulin, null Régine Cartier, null Geoffroy Hariri, null Dorothée Chopin, null Camille Vatier, null Nathalie Bourcigaux, null Emmanuelle Chaigneau, null Sophie Christin‐Maitre, null Bruno Donadille, null Bruno Feve, null Sophie Lamothe, null Julie Sarfati, null Pascal Pernet, null Anne Chambon, null Delphine Demarsy, null Hugo Campagne, null Françoise Latil‐Plat, null Monica Berne, null Marilyne Grinand, null Marion Touzet, null Aydrey Zabulon, null Jocelyne Craspag, null Catherine Ledoux, null Cedric Contaret, null Blandine Janand‐Delenne, null Anaïs Giraud, null Marie Lou Lacrimini, null Joëlle Arrivie, null Deborah Ancelle, null Carine Guillois, null Bénédicte Fremy, null Amina Chaalal, null Gaëlle Barrande, null Anne Dorange, null Eglantine Rouanet, null Dominique Seret‐Begue, null Audrey Saoud, null Anne‐Marie Guedj, null Nathalie Bedos, null Fritz‐Line Velayoudom, null Marie Dumas, null Benoite Gonda, null Christine Coffin, null Stéphanie Gibiat, null Myriam Lungo, null Chantal Bully, null Pierre Serusclat, null Stella Bully, null Patricia Carre, null Jean‐Philippe Leberre, null Carlos Elkhoury, null Marine Thieux, null Laetitia Paradisi‐Prieur, and null CORONADO investigators
- Subjects
Vaccination ,Pediatrics ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Hospitalized patients ,Diabetes mellitus ,Medicine ,business ,medicine.disease - Published
- 2021
- Full Text
- View/download PDF
23. Unilateral nonhaemorrhagic adrenal infarction as a cause of abdominal pain during pregnancy
- Author
-
F. Chasseloup, Sophie Christin-Maitre, and N. Bourcigaux
- Subjects
Adult ,medicine.medical_specialty ,Abdominal pain ,Endocrinology, Diabetes and Metabolism ,Hemodynamics ,030209 endocrinology & metabolism ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Pregnancy ,Antiphospholipid syndrome ,Internal medicine ,Adrenal Glands ,medicine ,Humans ,Adrenal infarction ,cardiovascular diseases ,030219 obstetrics & reproductive medicine ,business.industry ,Obstetrics and Gynecology ,medicine.disease ,Abdominal Pain ,Pregnancy Complications ,Infarction ,Cardiology ,Female ,medicine.symptom ,Tomography, X-Ray Computed ,Adrenal Hemorrhage ,business - Abstract
Adrenal infarction is usually associated with bilateral adrenal hemorrhage in the setting of antiphospholipid syndrome or hemodynamic variation. Few cases of unilateral nonhemorrhagic adrenal infarction (NHAI) have been described in the literature. Here, we report a case occurring during pregnancy. A 30-year-old woman presented at 32 weeks of gestation with sudden-onset right abdominal pain and contractions. Unilateral adrenal infarction was diagnosed following computed tomography (CT). It showed an enlarged right adrenal, without hyperenhancement. Because of persisting contractions, despite medical care, she delivered a healthy, albeit premature, girl. Abdominal pain decreased right after delivery. Three month later, CT imaging showed atrophy of the right adrenal and a normal left adrenal. The patient's adrenal hormonal function was normal. Accurate diagnosis of NHAI remains difficult as its clinical presentation is not specific. It can only be performed with adrenal imaging. Magnetic resonance imaging shows diffuse enlargement of one or both adrenals and an edema on T2-weighted images. Anticoagulation therapy may be discussed. Patients should be evaluated between 3 and 6 months after the event to assess adrenal size and function. In summary, NHAI during pregnancy is probably underdiagnosed and obstetricians should be aware of this or diagnostic difficulty.
- Published
- 2019
- Full Text
- View/download PDF
24. Unraveling a case of 46,XY DSD due to 17ß-Hydroxysteroid Dehydrogenase type 3 mutations at the age of 49
- Author
-
Aubin Garcia, Marie Legendre, Sandra Chantot-Bastaraud, Jean-Pierre Siffroi, Sophie Christin-Maitre, Centre de référence des Maladies Endocriniennes Rares de la Croissance [CHU Saint-Antoine AP-HP] (CRMERC), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], UF de Génétique moléculaire [CHU Trousseau], CHU Trousseau [APHP], UF de Génétique chromosomique [CHU Trousseau], and Couvet, Sandrine
- Subjects
[SDV] Life Sciences [q-bio] ,Difference of Sexual Development ,primary amenorrhea ,Endocrinology ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,[SDV]Life Sciences [q-bio] ,Endocrinology, Diabetes and Metabolism ,17-ß Hydroxysteroid Dehydrogenase type 3 ,XY DSD ,General Medicine ,Variation of sexual development ,[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics - Abstract
International audience; 17-ß Hydroxysteroid dehydrogenase type 3 (17β-HSD3) is an enzyme transforming Delta 4 androstenedione into testosterone. It is involved in the early development of the male genital tract. In this case report, we describe a 46,XY Difference of Sexual Development (DSD) individual with a female phenotype, primary amenorrhea, facial dysmorphia and mental retardation. Gene sequencing using a panel of genes involved in DSD revealed two heterozygous loss-of-function mutations in the HSD17B3 enzyme. Furthermore, a microarray analysis revealed a 37Mb segmental 3p duplication and a recurrent 16p13.11 microduplication. The large 3p duplication is responsible for her mental retardation and her facial dysmorphia. Interestingly, HSD17B3 mutations were identified only in adulthood, at the age of 49. Furthermore, the patient's severe mental retardation and facial dysmorphia are due to genetic abnormalities different from the ones involved in her DSD
- Published
- 2021
- Full Text
- View/download PDF
25. Monitoring gestational diabetes mellitus patients with the telemedicine application MyDiabby decreases the rate of foetal macrosomia
- Author
-
Guillaume Girard, Pr Sophie Christin-Maitre, Celine De Carne, Isabelle Gueguen, Jean-Claude Buzzi, Camille Vatier, Tiphaine Meykiechel, and Nathalie Bourcigaux
- Subjects
Telemedicine ,medicine.medical_specialty ,Obstetrics ,business.industry ,Endocrinology, Diabetes and Metabolism ,Pregnancy Outcome ,General Medicine ,medicine.disease ,Fetal Macrosomia ,Gestational diabetes ,Foetal macrosomia ,Diabetes, Gestational ,Endocrinology ,Pregnancy ,Internal Medicine ,medicine ,Humans ,Female ,business - Published
- 2021
26. Pituitary adenoma in patients with multiple endocrine neoplasia type 1: a cohort study
- Author
-
Helene Leclerc, Albert Beckers, Sébastien Gaujoux, Olivia Rousseau, Antoine Tabarin, Sarra Smati, Pierre Goudet, Françoise Borson-Chazot, Philippe Ruszniewski, Catherine Bauters, Brigitte Delemer, Bernard Goichot, Samy Hadjadj, T. Cuny, Sophie Christin-Maitre, Bruno Vergès, Maëlle Le Bras, Bertrand Cariou, Isabelle Raingeard, Philippe Caron, Philippe Chanson, Frederic Castinetti, Matthieu Wargny, Isabelle Guilhem, PHU 2 - Institut du Thorax et du Sytème Nerveux [CHU Nantes] (ITSN), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre hospitalier universitaire de Nantes (CHU Nantes), CHU Dijon, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Aix Marseille Université (AMU), CHU Lille, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Hôpital Haut-Lévêque - CHU de Bordeaux (Centre médico chirurgical Magellan), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Hôpital Beaujon [AP-HP], Université Paris Cité (UPCité), Hospices Civils de Lyon (HCL), Hôpital Sud [CHU Rennes], CHU Pontchaillou [Rennes], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital de Hautepierre [Strasbourg], Centre Hospitalier Universitaire de Liège (CHU-Liège), AP-HP Hôpital universitaire Robert-Debré [Paris], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Nantes Université (Nantes Univ), and the GTE (Groupe d’étude des Tumeurs Endocrine) study group
- Subjects
Adult ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Population ,Asymptomatic ,Cohort Studies ,Endocrinology ,Pituitary adenoma ,Internal medicine ,medicine ,Multiple Endocrine Neoplasia Type 1 ,Endocrine system ,Humans ,MEN1 ,Pituitary Neoplasms ,Multiple endocrine neoplasia ,education ,Retrospective Studies ,education.field_of_study ,business.industry ,General Medicine ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Cohort ,Female ,medicine.symptom ,business ,Cohort study - Abstract
Objective Pituitary adenoma (PA) is one of the three major components of multiple endocrine neoplasia type 1 (MEN1). Recent studies have suggested that MEN1-associated PAs are less aggressive than initially estimated. We propose an analysis of the outcome of PAs with a standard of care treatment in a nationwide cohort of MEN1 patients. Design Retrospective observational nationwide cohort study using the MEN1 patient registry from the French Group of Endocrine Tumours (GTE). Methods The GTE database population consists of 1435 patients with MEN1. This analysis focused on 551 patients recruited after 2000 with at least 3 years of follow-up. The study outcome was tumour progression of PA defined by an increase in Hardy classification (HC) during follow-up according to referring physician regular reports. Results Among 551 MEN1 patients (index and related), 202 (36.7%) had PA, with 114 (56.4%) diagnosed by MEN1-related screening. PAs were defined according to HC as microadenoma (grade I) in 117 cases (57.9%), macroadenoma in 59 (29.2%) with 20 HC grade II and 39 HC grades III–IV and unspecified in 26 (12.8%). They were prolactinomas in 92 cases (45.5%) and non-secreting in 73 (36.1%). After a median follow-up of 3 years among the 137 patients with HC grades I–II, 4 patients (2.9%) presented tumour progression. Conclusion PAs in patients with MEN1 are less aggressive than previously thought. Tumour progression is rare with a standard of care monitoring and treatment, especially in related patients who mostly present non-secreting microadenoma. MRI monitoring for asymptomatic MEN1 patients should be reduced accordingly.
- Published
- 2021
- Full Text
- View/download PDF
27. Adrenal ganglioneuromas: a retrospective multicentric study of 104 cases from the COMETE network
- Author
-
Natacha Driessens, Caroline Storey, Frédéric Illouz, Laurence Amar, Hervé Lefebvre, Marie-Christine Vantyghem, Jérôme Bertherat, Laurent Brunaud, Eric Baudin, Peggy Renoult-Pierre, Isabelle Raingeard, Delphine Vezzosi, Emmanuelle Vidal-Petiot, Nicolas Chevalier, Marie-Laure Raffin-Sanson, Antoine-Guy Lopez, Bénédicte Decoudier, Michel Peuchmaur, Christel Jublanc, Delphine Drui, Pierre Goudet, Sophie Christin-Maitre, Antoine Tabarin, Aurelien Morini, Christiane Ajzenberg, Elisa Deflorenne, O. Gilly, and Charlotte Lussey
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,Adrenal Gland Neoplasms ,Age at diagnosis ,Computed tomography ,Scintigraphy ,Community Networks ,Cohort Studies ,Young Adult ,Endocrinology ,Belgium ,Hounsfield scale ,Histological diagnosis ,Internal medicine ,medicine ,Humans ,Ganglioneuroma ,Age of Onset ,Child ,Aged ,Retrospective Studies ,medicine.diagnostic_test ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Neuroblastic Tumor ,Treatment Outcome ,Child, Preschool ,Female ,Radiology ,France ,Neoplasm Recurrence, Local ,business ,Follow-Up Studies - Abstract
Objective Adrenal ganglioneuromas are rare, differentiated, neuroblastic tumors that originate from the peripheral sympathetic nervous system. Because of their rarity, information is limited, derived from small cases series. Our objective was to characterize this tumor and provide help for its management. Methods A retrospective multicenter analysis of adrenal ganglioneuromas from 20 French centers belonging to the COMETE network and one Belgian center. Results Among the 104 cases identified, 59.6% were women (n = 62/104), median age at diagnosis was 29 years, with 24 pediatric cases. 60.6% (n = 63/104) were incidentalomas. Ganglioneuromas were non-secreting tumors in 90.8% of cases (n = 89/98), whereas the preoperative hormonal evaluation was indeterminate for 9.2% of patients (n = 9/98). CT imaging, performed on 96 patients, revealed large tumors (median diameter of 50 mm) with a non-contrast density > 10 Hounsfield units in 98.1% (n = 52/53) and calcifications in 64.6% of cases (n = 31/48). Increased uptake on 123I-MIBG scintigraphy and 18F-FDG-PET/CT was observed in 26.7% (n = 8/30) and 42.2% (n = 19/45) of the tumors, respectively. All 104 patients underwent surgery. No recurrence was observed among the 42 patients who had an imaging follow-up (mean 29.6 months, median 18 months (4–156)). Conclusion Adrenal ganglioneuromas are large tumors, mostly nonfunctioning, without benign imaging features. Although the duration of follow-up was limited in our series, no recurrence was identified. A review of the literature confirms the absence of postoperative recurrence. Based on all available data, in the absence of special circumstances (genetic form, uncertain histological diagnosis), long-term follow-up is not necessary after complete surgery for patients with an adrenal ganglioneuroma.
- Published
- 2021
28. Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome)
- Author
-
Régis Coutant, Maud Bidet, Sophie Catteau-Jonard, Geneviève Plu-Bureau, Anne Bachelot, Lise Duranteau, Phillipe Touraine, Aude Brac de la Perriere, Juliane Léger, Justine Hugon-Rodin, Jean-Pierre Siffroi, Jean Victor Blanc, Véronique Kerlan, Michael Grynberg, Micheline Misrahi, Muriel Houang, Sophie Christin-Maitre, Jean Claude Carel, Michel Polak, Charlotte Sonigo, Delphine Zenaty, B. Donadille, Claire Bouvattier, Laïla El-Khattabi, Frédérique Albarel, Nicolas Chevalier, Maria Givony, Rachel Reynaud, Catherine Pienkowski, Couvet, Sandrine, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université (SU), Centre de référence des Maladies Endocriniennes Rares de la Croissance [CHU Saint-Antoine AP-HP] (CRMERC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance Publique - Hôpitaux de Marseille (APHM), CHU Pitié-Salpêtrière [AP-HP], Clinique mutualiste La Sagesse, Université Paris-Saclay, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Hospices Civils de Lyon (HCL), Hôpital Jeanne de Flandre [Lille], Université Côte d'Azur (UCA), Hôpital Robert Debré, Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier Saint-Joseph [Paris], CHU Trousseau [APHP], AP-HP - Hôpital Antoine Béclère [Clamart], Université de Brest (UBO), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Robert Debré Paris, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), CHU Necker - Enfants Malades [AP-HP], Hôpital de la Timone [CHU - APHM] (TIMONE), Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], and UF de Génétique chromosomique [CHU Trousseau]
- Subjects
Adult ,Anti-Mullerian Hormone ,Pediatrics ,medicine.medical_specialty ,Hormone Replacement Therapy ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Primary ovarian insufficiency ,Premature ovarian insufficiency ,[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics ,MESH: Fragile X Mental Retardation Protein ,X chromosome ,Fragile X Mental Retardation Protein ,Endocrinology ,Turner syndrome ,MESH: Follicle Stimulating Hormone ,medicine ,Hormonal replacement therapy ,Humans ,Chemotherapy ,MESH: Humans ,business.industry ,Oocyte donation ,MESH: Hormone Replacement Therapy ,MESH: Adult ,General Medicine ,MESH: Primary Ovarian Insufficiency ,medicine.disease ,FMR1 ,Radiation therapy ,[SDV] Life Sciences [q-bio] ,MESH: France ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,Transgender hormone therapy ,Etiology ,MESH: Anti-Mullerian Hormone ,Female ,France ,Follicle Stimulating Hormone ,business ,FMR1 premutation ,MESH: Female ,Hormone - Abstract
International audience; Premature ovarian insufficiency (POI) is a rare pathology affecting 1-2% of under-40 year-old women, 1 in 1000 under-30 year-olds and 1 in 10,000 under-20 year-olds. There are multiple etiologies, which can be classified as primary (chromosomal, genetic, auto-immune) and secondary or iatrogenic (surgical, or secondary to chemotherapy and/or radiotherapy). Despite important progress in genetics, more than 60% of cases of primary POI still have no identifiable etiology; these cases are known as idiopathic POI. POI is defined by the association of 1 clinical and 1 biological criterion: primary or secondary amenorrhea or spaniomenorrhea of>4 months with onset before 40 year of age, and elevated follicle-stimulating hormone (FSH)>25IU/L on 2 assays at>4 weeks' interval. Estradiol level is low, and anti-Müllerian hormone (AMH) levels have usually collapsed. Initial etiological work-up comprises auto-immune assessment, karyotype, FMR1 premutation screening and gene-panel study. If all of these are normal, the patient and parents may be offered genome-wide analysis under the "France Génomique" project. The term ovarian insufficiency suggests that the dysfunction is not necessarily definitive. In some cases, ovarian function may fluctuate, and spontaneous pregnancy is possible in around 6% of cases. In confirmed POI, hormone replacement therapy is to be recommended at least up to the physiological menopause age of 51 years. Management in a rare diseases center may be proposed.
- Published
- 2021
- Full Text
- View/download PDF
29. Heart and Turner syndrome
- Author
-
Sophie Christin-Maitre, Bruno Donadille, Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de référence des maladies endocriniennes rares de la croissance et du développement [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
medicine.medical_specialty ,bicuspid aortic valve ,Heart disease ,Maladie cardiaque ,Endocrinology, Diabetes and Metabolism ,Population ,rare disease ,Turner Syndrome ,030209 endocrinology & metabolism ,Grossesse Maladie rare ,Aortic Coarctation ,Coarctation aortique ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Bicuspid aortic valve ,[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system ,Internal medicine ,Turner syndrome ,medicine ,Humans ,aortic dissection ,education ,Aortic dissection ,education.field_of_study ,Pregnancy ,medicine.diagnostic_test ,business.industry ,Infant, Newborn ,Magnetic resonance imaging ,Syndrome de Turner ,Heart ,General Medicine ,aortic dilatation ,medicine.disease ,Magnetic Resonance Imaging ,Dissection aortique ,3. Good health ,030220 oncology & carcinogenesis ,Valve aortique bicuspide ,Cardiology ,[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie ,Female ,pregnancy ,Dilatation aortique ,business ,Rare disease - Abstract
International audience; Turner syndrome (TS) is a rare disease (ORPHA #881) which affects about 50 in 100 000 newborn girls. Their karyotype shows a complete or partial loss of the second X chromosome. In TS, congenital cardiovascular malformations, such as bicuspid aortic valves and aortic coarctation are frequent, affecting 20-30% and 7-18% of the TS population, respectively. The morbidity and mortality of these patients are high and related to the presence of hypertension and/or aortic dilatation (40%), inducing aortic dissection. European guidelines published in 2017 have indicated how to monitor patients using magnetic resonance imaging (MRI) and/or echography. Different studies have shown that a cardiovascular lifelong follow-up is necessary and therefore education of patients with TS and their families represents a major issue. This review will present recent data concerning the progression of aortic diameters as well as current molecular knowledge of the cardiovascular system in patients with TS.; Le syndrome de Turner (TS) est une maladie rare (ORPHA # 881) qui touche environ 50 nouveau-nés sur 100 000. Leur caryotype montre une perte complète ou partielle du deuxième chromosome X. Dans le TS, les malformations cardiovasculaires congénitales, telles que les valves aortiques bicuspides et la coarctation aortique sont fréquentes, affectant respectivement 20-30 % et 7-18 % de la population TS. La morbidité et la mortalité de ces patients sont élevées et liées à la présence d’hypertension et/ou de dilatation aortique (40 %), induisant une dissection aortique. Les directives européennes publiées en 2017 ont indiqué comment surveiller les patients par imagerie par résonance magnétique (IRM) et/ou échographie. Différentes études ont montré qu’un suivi cardiovasculaire tout au long de la vie est nécessaire et que l’éducation des patients TS et de leurs familles représente donc un enjeu majeur. Cette revue présentera des données récentes concernant la progression des diamètres aortiques ainsi que les connaissances moléculaires actuelles du système cardiovasculaire chez les patients atteints de TS.
- Published
- 2020
- Full Text
- View/download PDF
30. Prevalence and progression of aortic dilatation in adult patients with Turner syndrome: a cohort study
- Author
-
Clément Cholet, Nathalie Bourcigaux, Alexandra Rousseau, Laurence Iserin, Mariana Nedelcu, Sophie Christin-Maitre, B. Donadille, Sophie Tuffet, L Monnier-Cholley, Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Service de pharmacologie - Dosage de médicaments [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service de Radiologie [CHU Saint-Antoine], Hôpital Européen Georges Pompidou [APHP] (HEGP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
- Subjects
Adult ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,[SDV]Life Sciences [q-bio] ,Aortic Diseases ,Heart Valve Diseases ,Turner Syndrome ,030209 endocrinology & metabolism ,Thyroiditis ,Cohort Studies ,03 medical and health sciences ,Young Adult ,0302 clinical medicine ,Endocrinology ,Bicuspid aortic valve ,Bicuspid Aortic Valve Disease ,Internal medicine ,medicine.artery ,Turner syndrome ,Ascending aorta ,Prevalence ,Medicine ,Humans ,Aorta ,Aortic dissection ,Body surface area ,business.industry ,Hazard ratio ,General Medicine ,medicine.disease ,030220 oncology & carcinogenesis ,Aortic Valve ,Cohort ,Cardiology ,Disease Progression ,cardiovascular system ,Female ,France ,business ,Dilatation, Pathologic - Abstract
Objective: Turner syndrome (TS) is a rare disorder affecting 1/2500 female newborn. Aortic dilatation (AD) and aortic dissection represent a major concern in TS. The aims of our study were to describe the aortic root growth, potential aortic dilatation (AD) risk factors and cardiovascular outcomes in a cohort of patients with TS. Methods: Among 204 adult patients included, 197 were studied using a standardized 1.5 Tesla MRI protocol. AD was defined as an aortic diameter ≥20 mm/m2 at the Valsalva sinuses and/or at the ascending aorta, when indexed to body surface area. Results: At baseline, AD was present in 81/197 (41.1%) and 32/197 (16.2%) of patients, at the levels of Valsalva and ascending aorta, respectively. The aortic Valsalva diameter was larger in patients treated for thyroiditis (P < 0.001). Potential risk factors of AD were aging (P < 0.001) and the presence of bicuspid aortic valve (BAV) (P = 0.002). The hazard ratio (HR) of AD occurrence in the presence of BAV was 2.2 (95% CI: 1.33–3.71). After a median follow-up period of 5.1 years (n = 143), AD was present in 58/143 (40.6%) and 25/143 (17.5%) of patients at the levels of Valsalva and ascending aorta, respectively. The median aortic growth of the Valsalva sinuses remained stable. At the ascending aorta, it increased by 0.14 ± 0.61 mm/year. Only one aortic-related death was observed. Conclusion: AD is common in adult patients with TS. However, our results are rather reassuring, as the median aortic diameters remained stable after 5.1 years and few aortic events were observed.
- Published
- 2020
- Full Text
- View/download PDF
31. Added value of buccal cell FISH analysis in the diagnosis and management of Turner syndrome
- Author
-
N Bourcigaux, A. Khodawardi, Jean-Pierre Siffroi, A. Graff, Sophie Christin-Maitre, Camille Vatier, M.C. Villy, A. Borgel, B. Donadille, H. Morel, Sorbonne Université (SU), Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), UF de Génétique chromosomique [CHU Trousseau], Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], and Couvet, Sandrine
- Subjects
MESH: Mouth Mucosa ,[SDV]Life Sciences [q-bio] ,Buccal swab ,blood karyotype ,Turner Syndrome ,[SDV.GEN] Life Sciences [q-bio]/Genetics ,Cohort Studies ,0302 clinical medicine ,Turner syndrome ,Medicine ,X/46 ,Prospective Studies ,MESH: Cohort Studies ,Ovarian Neoplasms ,030219 obstetrics & reproductive medicine ,medicine.diagnostic_test ,Mosaicism ,Rehabilitation ,Obstetrics and Gynecology ,[SDV] Life Sciences [q-bio] ,MESH: Ovarian Neoplasms ,buccal cells FISH ,Cohort ,Female ,MESH: Mosaicism ,Cohort study ,Adult ,medicine.medical_specialty ,MESH: Turner Syndrome ,Urinary system ,Gonadoblastoma ,030209 endocrinology & metabolism ,[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics ,03 medical and health sciences ,Internal medicine ,Humans ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,MESH: Humans ,business.industry ,Mouth Mucosa ,Turner’s syndrome ,MESH: Adult ,Buccal administration ,medicine.disease ,MESH: Prospective Studies ,Reproductive Medicine ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,Skin biopsy ,business ,MESH: Female ,X monosomy ,XX mosaicism - Abstract
STUDY QUESTION Is there an added diagnosis value of buccal cell FISH analysis compared with blood lymphocyte chromosomal investigations in patients with Turner syndrome (TS)? SUMMARY ANSWER Buccal cell FISH analysis, a non-invasive technique, modified the chromosomal results obtained with the blood karyotype in 17 patients (12%) of our cohort. WHAT IS KNOWN ALREADY Few studies have evaluated buccal cell FISH analysis and compared them with blood karyotype in patients with TS. STUDY DESIGN, SIZE, DURATION A prospective, monocentric cohort study was conducted in a rare diseases centre (CMERC) between July 2017 and August 2019. PARTICIPANTS/MATERIALS, SETTING, METHODS In total, 142 adult patients with TS, and at least 5% 45,X cells in a previous blood karyotype, were recruited. All the patients’ files were included in the CEMARA database. This national database has been declared to the French data protection agency (CNIL approval number 1187326). In compliance with French law, consent regarding non-opposition to collect and use the data was obtained from each patient. A FISH analysis on a buccal smear was performed. MAIN RESULTS AND THE ROLE OF CHANCE The percentage of 45,X cells was identical between the two tissues in only 32.4% of cases. The discrepancy was higher than 41% for 12% of the cohort. The percentage of 45,X cells was higher in blood in 53 (37.3%) patients, and higher in buccal cells in 43 (30.3%) of cases. In 17 (12%) cases, the blood karyotype had to be reconsidered in regard to the buccal cell analysis. LIMITATIONS, REASONS FOR CAUTION It would have been interesting to evaluate karyotypes in cells from other tissues such as cells from skin biopsy or from the urinary tract and even from blood vessels or gonads in case of surgery and to compare them with each patient’s phenotype. However, most of the time, these tissues are not available. WIDER IMPLICATIONS OF THE FINDINGS Although blood lymphocyte karyotype remains the gold standard for the diagnosis of TS, buccal cell FISH analysis is an efficient tool to evaluate the global chromosomal constitution in these patients, thus allowing them to have better care and follow-up. For instance, identifying a Y chromosome can prevent the occurrence of a gonadoblastoma, as gonadectomy should be discussed. On the other hand, finding normal XX cells in a patient with a previous diagnosis of homogenous 45,X TS, may be psychologically helpful and relevant for gynaecological care. STUDY FUNDING/COMPETING INTEREST(S) No specific funding was sought for the study. The authors declare no competing interests. TRIAL REGISTRATION NUMBER N/A, N/A.
- Published
- 2020
- Full Text
- View/download PDF
32. Next Generation Sequencing Should Be Proposed to Every Woman With 'Idiopathic' Primary Ovarian Insufficiency
- Author
-
Denise Molina-Gomes, Geneviève Plu-Bureau, Anne Bachelot, Didier Dewailly, Sarah Eskenazi, Sophie Catteau-Jonard, Justine Hugon-Rodin, Catherine Dodé, Anne Gompel, Sophie Christin-Maitre, and Philippe Touraine
- Subjects
0301 basic medicine ,Candidate gene ,medicine.medical_specialty ,endocrine system ,phenotype ,Endocrinology, Diabetes and Metabolism ,Ethnic origin ,Primary ovarian insufficiency ,DNA sequencing ,FSHB ,03 medical and health sciences ,0302 clinical medicine ,FIGLA ,Internal medicine ,Genotype ,Medicine ,Family history ,Clinical Research Articles ,next generation sequencing ,030219 obstetrics & reproductive medicine ,business.industry ,genetic results ,030104 developmental biology ,Cohort ,business ,AcademicSubjects/MED00250 - Abstract
Context Primary ovarian insufficiency (POI) affects 1% of women under 40 years of age. POI is idiopathic in more than 70% of cases. Though many candidate genes have been identified in recent years, the prevalence and pathogenicity of abnormalities are still difficult to establish. Objective Our primary objective was to evaluate the prevalence of gene variations in a large prospective multicentric POI cohort. Our secondary objective was to evaluate the correlation between phenotype and genotype. Methods Two hundred and sixty-nine well-phenotyped POI patients were screened for variants of 18 known POI genes (BMP15, DMC1, EIF2S2, FIGLA, FOXL2, FSHR, GDF9, GPR3, HFM1, LHX8, MSH5, NOBOX, NR5A1, PGRMC1, STAG3, XPNPEP2, BHLB, and FSHB) by next generation sequencing (NGS). Abnormalities were classified as “variant” or “variant of unknown signification” (VUS) according to available functional tests or algorithms (SIFT, Polyphen-2, MutationTaster). Results One hundred and two patients (38%) were identified as having at least 1 genetic abnormality. Sixty-seven patients (25%) presented at least 1 variant. Forty-eight patients presented at least 1 VUS (18%). Thirteen patients (5%) had combined abnormalities. NOBOX variants were the most common gene variants involved in POI (9%). Interestingly, we saw no significant differences in the previous family history of POI, ethnic origin, age at onset of POI, primary amenorrhea, or secondary menstrual disturbances between the different genotypes. Conclusion In our study, a high percentage of patients presented gene variants detected by NGS analysis (38%). Every POI patient should undergo NGS analysis to improve medical cares of the patients.
- Published
- 2020
33. Gonad differentiation toward ovary
- Author
-
Sophie Christin-Maitre, Sophie Lamothe, Valérie Bernard, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Sorbonne Université (SU)
- Subjects
Male ,endocrine system ,Gonad ,Sex Differentiation ,Endocrinology, Diabetes and Metabolism ,Female Phenotype ,[SDV]Life Sciences [q-bio] ,030209 endocrinology & metabolism ,Ovary ,Biology ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,medicine ,Animals ,Humans ,Gonads ,Sexual Development ,Chromosome ,Gene Expression Regulation, Developmental ,Cell Differentiation ,General Medicine ,Sex Determination Processes ,Phenotype ,Cell biology ,Testis determining factor ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Genital tract ,Female ,Hormone - Abstract
Gonad differentiation depends on a set of cellular and hormonal signals interacting in a specific order, with very precise windows of action, to contribute to the establishment of the genital tract and a male or female phenotype. Research initially focused on the stages of gonad differentiation toward testis, in particular following the identification in 1990 of the SRY factor on chromosome Y. The mechanisms involved in gonad differentiation toward ovary took longer to identify. Thanks to patients with different sexual development (DSD) and animal knock-out models, description of the cascades involved in the activation and maintenance of ovarian development has progressed considerably in recent years.
- Published
- 2020
- Full Text
- View/download PDF
34. Looking at New Unexpected Disease Targets in LMNA-Linked Lipodystrophies in the Light of Complex Cardiovascular Phenotypes: Implications for Clinical Practice
- Author
-
Stéphane Ederhy, Elisabeth Sarrazin, B. Donadille, Olivier Lascols, Fabien Picard, Bruno Fève, Isabelle Jéru, Corinne Vigouroux, Karim Wahbi, Camille Vatier, Ariel Cohen, Héléna Mosbah, Sophie Benabbou, Pascale Richard, Sophie Christin-Maitre, Marie-Christine Vantyghem, B. Neraud, Alban Redheuil, Jocelyn Inamo, Franck Boccara, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Recherche translationnelle sur le diabète - U 1190 (RTD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHU de la Martinique [Fort de France], Hôpital Pierre Zobda-Quitman [CHU de la Martinique], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Hôpital Foch [Suresnes], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Filière Neuromusculaire (FILNEMUS), Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire d'Imagerie Biomédicale [Paris] (LIB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Paris-Centre de Recherche Cardiovasculaire (PARCC (UMR_S 970/ U970)), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre de Recherche Saint-Antoine (CR Saint-Antoine), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP], Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], Service de Cardiologie [CHU Saint-Antoine], Laboratoire commun de biologie et génétique moléculaires [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Unité Fonctionnelle de Cardiogénétique et Myogénétique Moléculaire et Cellulaire, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Service de Biochimie Métabolique [CHU Pitié-Salpêtrière], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'Imagerie Biomédicale (LIB), Service de radiologie cardiovasculaire et interventionnelle [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Gestionnaire, Hal Sorbonne Université, and Service de Radiologie cardiovasculaire et interventionnelle [CHU Pitié-Salpêtrière]
- Subjects
0301 basic medicine ,medicine.medical_specialty ,lipodystrophy ,[SDV]Life Sciences [q-bio] ,Cardiomyopathy ,LMNA ,030204 cardiovascular system & hematology ,Progeroid syndromes ,03 medical and health sciences ,0302 clinical medicine ,lmna ,cardiovascular disease ,Internal medicine ,medicine ,lcsh:QH301-705.5 ,Coronary atherosclerosis ,[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology ,business.industry ,Generalized lipodystrophy ,Partial Lipodystrophy ,Dilated cardiomyopathy ,General Medicine ,medicine.disease ,3. Good health ,[SDV] Life Sciences [q-bio] ,030104 developmental biology ,lcsh:Biology (General) ,Cardiology ,Lipodystrophy ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Variants in LMNA, encoding A-type lamins, are responsible for laminopathies including muscular dystrophies, lipodystrophies, and progeroid syndromes. Cardiovascular laminopathic involvement is classically described as cardiomyopathy in striated muscle laminopathies, and arterial wall dysfunction and/or valvulopathy in lipodystrophic and/or progeroid laminopathies. We report unexpected cardiovascular phenotypes in patients with LMNA-associated lipodystrophies, illustrating the complex multitissular pathophysiology of the disease and the need for specific cardiovascular investigations in affected patients. A 33-year-old woman was diagnosed with generalized lipodystrophy and atypical progeroid syndrome due to the newly identified heterozygous LMNA p.(Asp136Val) variant. Her complex cardiovascular phenotype was associated with atherosclerosis, aortic valvular disease and left ventricular hypertrophy with rhythm and conduction defects. A 29-year-old woman presented with a partial lipodystrophy syndrome and a severe coronary atherosclerosis which required a triple coronary artery bypass grafting. She carried the novel heterozygous p.(Arg60Pro) LMNA variant inherited from her mother, affected with partial lipodystrophy and dilated cardiomyopathy. Different lipodystrophy-associated LMNA pathogenic variants could target cardiac vasculature and/or muscle, leading to complex overlapping phenotypes. Unifying pathophysiological hypotheses should be explored in several cell models including adipocytes, cardiomyocytes and vascular cells. Patients with LMNA-associated lipodystrophy should be systematically investigated with 24-h ECG monitoring, echocardiography and non-invasive coronary function testing.
- Published
- 2020
- Full Text
- View/download PDF
35. Qualité du sperme et fertilité : rôle de l’environnement et de la santé
- Author
-
Véronique Kerlan, Sophie Lamothe, and Sophie Christin-Maitre
- Subjects
0301 basic medicine ,Infertility ,030219 obstetrics & reproductive medicine ,urogenital system ,Endocrinology, Diabetes and Metabolism ,media_common.quotation_subject ,Longevity ,Sperm dna ,Physiology ,Fertility ,General Medicine ,Biology ,medicine.disease ,biology.organism_classification ,Male infertility ,03 medical and health sciences ,Semen quality ,030104 developmental biology ,0302 clinical medicine ,Endocrinology ,medicine ,Epigenetics ,Caenorhabditis elegans ,media_common - Abstract
Sperm quality appears to be degrading over the past 40 years. Nowadays, more than 35 % of causes of male infertility are still idiopathic. More and more studies have suggested an impact of environment on sperm quality, essentially through epigenetic and hormonal changes. Recent studies in men with impaired sperm quality, have demonstrated epigenetic variations in sperm DNA. These modifications are responsible for modifications of the expression of transmissible genes to theiroffspring. Those transgenerational effects have been particularly illustrated in drosophila and caenorhabditis elegans. In humans, consequences of the environment on fertility have been studied in obese men, who present hypogonadotropic as well as hypergonadotropic hypogonadisms. Interestingly, recent studies have suggested a correlation between sperm quality and longevity. In summary, those environmental factors are the source of new causes of infertility.
- Published
- 2018
- Full Text
- View/download PDF
36. Severe Congenital Adrenal Hyperplasia Presenting as Bilateral Testicular Tumors and Azoospermia in the Third Decade of Life
- Author
-
Isabelle Keller, Camille Vatier, Sophie Christin-Maitre, Jérôme Guéchot, Christine Bellanné-Chantelot, and Julie Sarfati
- Subjects
Azoospermia ,Pathology ,medicine.medical_specialty ,business.industry ,azoospermia ,Endocrinology, Diabetes and Metabolism ,Case Report ,030209 endocrinology & metabolism ,medicine.disease ,Molecular analysis ,03 medical and health sciences ,0302 clinical medicine ,Blood pressure ,21 hydroxylase deficiency ,adrenal tumors ,Reproductive Biology and Sex-Based Medicine ,030220 oncology & carcinogenesis ,TARTs ,medicine ,Precocious puberty ,Endocrine system ,Congenital adrenal hyperplasia ,business ,Salt-wasting ,Adrenal tumors - Abstract
Classic forms of 21-hydroxylase deficiency (21OHD) are usually diagnosed at birth by salt wasting or precocious puberty in male patients. Here we report the case of a 32-year-old male patient who presented with azoospermia and bilateral testicular tumors. He was referred to our endocrine unit after testicular surgery. His gonadotropins were undetectable. Liquid chromatography–tandem mass spectrometry revealed a high serum progesterone level, high 17-hydroxyprogesterone (17OHP) (255 ng/mL), and high levels of 17OHP metabolites, suggesting a classic form of 21OHD. His blood pressure was normal. Molecular analysis showed a homozygous large 21-hydroxylase gene (CYP21A2) conversion. Furthermore, an adrenal CT scan revealed voluminous, heterogeneous bilateral and asymmetric adrenal masses containing calcifications. Our case report illustrates the fact that a classic form of 21OHD can be diagnosed in late adulthood, manifested by azoospermia and large adrenal tumors, associated with elevated 17OHP., We describe a severe form of 21OHD diagnosed in late adulthood, in front of bilateral testicular tumors, azoospermia, and large bilateral adrenal masses, mimicking adrenocortical carcinoma.
- Published
- 2018
- Full Text
- View/download PDF
37. Impact on testicular function of a single ablative activity of 3.7 GBq radioactive iodine for differentiated thyroid carcinoma
- Author
-
J Fromigue, Martin Schlumberger, I. Berthaud, Tabassome Simon, Sylvie Brailly-Tabard, F. de Vathaire, I Petrot-Keller, Laurence Leenhardt, B. Donadille, N. Bourcigaux, Jean-Pierre Siffroi, P. Bouchard, Carole Rubino, M E Toubert, Sophie Christin-Maitre, Couvet, Sandrine, Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Mode de vie, génétique et santé : études intégratives et transgénérationnelles (U1018 (Équipe 9)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Université Paris-Saclay, Service de Biologie de la reproduction - Centre d'Etude et de Conservation des Oeufs et du Sperme humains [CHU Tenon] (CECOS), CHU Tenon [AP-HP], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Médecine nucléaire [CHU Pitié-Salpétrière], CHU Pitié-Salpêtrière [AP-HP], Service de médecine nucléaire et biophysique [CHU Saint-Antoine], Service de Génétique Moléculaire Pharmacogénétique et Hormonologie [CHU Bicêtre], AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Signalisation Hormonale, Physiopathologie Endocrinienne et Métabolique, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Université Paris-Sud - Paris 11 (UP11), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de génétique et embryologie médicales [CHU Trousseau], CHU Trousseau [APHP], Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Sorbonne Université (SU), Institut Gustave Roussy (IGR), and Hôpital Foch [Suresnes]
- Subjects
Male ,MESH: Carcinoma ,Time Factors ,[SDV]Life Sciences [q-bio] ,Physiology ,inhibin B ,MESH: Risk Assessment ,Iodine Radioisotopes ,MESH: Hormones ,0302 clinical medicine ,Risk Factors ,MESH: Risk Factors ,Testis ,FSH ,Longitudinal Studies ,Prospective Studies ,MESH: Longitudinal Studies ,Prospective cohort study ,Testosterone ,MESH: Treatment Outcome ,[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,MESH: Middle Aged ,030219 obstetrics & reproductive medicine ,MESH: Testis ,MESH: Spermatozoa ,Rehabilitation ,Obstetrics and Gynecology ,Cell Differentiation ,MESH: Iodine Radioisotopes ,Middle Aged ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,Spermatozoa ,radioactive iodine therapy ,[SDV] Life Sciences [q-bio] ,Treatment Outcome ,MESH: Thyroid Neoplasms ,MESH: Young Adult ,Chromosome abnormality ,France ,Adult ,MESH: Cell Differentiation ,testicular function ,MESH: Radiation Dosage ,endocrine system ,Adolescent ,MESH: Radiotherapy, Adjuvant ,MESH: Radiation Injuries ,030209 endocrinology & metabolism ,DNA Fragmentation ,[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics ,MESH: Infertility, Male ,Radiation Dosage ,Risk Assessment ,Sperm Preservation ,sperm aneuploidy ,Young Adult ,03 medical and health sciences ,medicine ,Humans ,MESH: Chromosome Aberrations ,MESH: DNA Fragmentation ,Endocrine system ,Thyroid Neoplasms ,Radiation Injuries ,Infertility, Male ,Chromosome Aberrations ,MESH: Adolescent ,MESH: Humans ,business.industry ,Carcinoma ,MESH: Time Factors ,MESH: Adult ,medicine.disease ,Sperm bank ,Sperm ,Hormones ,MESH: Male ,MESH: Prospective Studies ,MESH: France ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,Reproductive Medicine ,MESH: Biomarkers ,Radiotherapy, Adjuvant ,business ,Biomarkers ,Hormone - Abstract
STUDY QUESTION What are the consequences of radioactive iodine (RAI) therapy for testicular function? SUMMARY ANSWER A single activity of 3.7 GBq RAI for differentiated thyroid carcinoma (DTC) treatment in young men transiently altered Sertoli cell function and induced sperm chromosomal abnormalities. WHAT IS KNOWN ALREADY Few studies, mainly retrospective, have reported the potential impacts of RAI on endocrine and exocrine testicular function. STUDY DESIGN, SIZE, DURATION A longitudinal prospective multi-center study on testicular function performed in DTC patients before a single 131I ablative activity of 3.7 GBq (V0) and at 3 months (V3) and 13 months (V13) after treatment. PARTICIPANTS/MATERIALS, SETTING, METHODS Forty male patients, aged 18-55 years, with DTC participated. Hormonal analysis included FSH, LH, testosterone and inhibin B serum levels at V0, V3 and V13. Furthermore, sperm parameters, DNA fragmentation and sperm chromosomal abnormalities were evaluated at each time points. The differences in all parameters, between V0-V3, V0-V13 and V3-V13, were analyzed, using a Wilcoxon test. MAIN RESULTS AND THE ROLE OF CHANCE Prior to RAI administration, all patients had normal gonadal function. At V3, a statistically significant increase in FSH levels and a decrease in inhibin B levels were observed and sperm concentration, as well as the percentage of morphologically normal spermatozoa, were significantly decreased (P < 0.0001). These modifications were transient as both sperm concentration and normal morphology rate returned to baseline values at V13. However, at this later time point, FSH and inhibin B levels were still impacted by RAI administration but remained in the normal range. Although no DNA fragmentation was observed at V3 nor V13, our study revealed a statistically significant increase in the number of sperm chromosomal abnormalities both at V3 (P < 0.001) and V13 (P = 0.01). LIMITATIONS, REASONS FOR CAUTION Among the 40 patients included in the study, only 24 had all the parameters available at all visits. WIDER IMPLICATIONS OF THE FINDINGS Prospective studies with longer term follow up would be helpful to determine whether the chromosome abnormalities persist. These studies would be required before sperm banking should be suggested for all patients. However, sperm preservation for DTC patients who require cumulative radioiodine activities higher than 3.7 GBq should be proposed. STUDY FUNDING/COMPETING INTEREST(S) This study was supported by the Programme Hospitalier de Recherche Clinique, AP-HP (No. P040419). The authors report no conflict of interest in this work. TRIAL REGISTRATION NUMBER NCT01150318.
- Published
- 2018
- Full Text
- View/download PDF
38. Human 3beta-hydroxysteroid dehydrogenase deficiency associated with normal spermatic numeration despite a severe enzyme deficit
- Author
-
Bruno Donadille, Sophie Christin-Maitre, Muriel Houang, Jean Pierre Siffroi, Irène Netchine, Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de référence des Maladies Endocriniennes Rares de la Croissance [CHU Saint-Antoine AP-HP] (CRMERC), Service d'explorations fonctionnelles [CHU Trousseau], CHU Trousseau [APHP], Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], and Couvet, Sandrine
- Subjects
endocrine system ,steroidogenesis ,puberty ,[SDV]Life Sciences [q-bio] ,Endocrinology, Diabetes and Metabolism ,media_common.quotation_subject ,Fludrocortisone ,Physiology ,030209 endocrinology & metabolism ,Fertility ,[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics ,lcsh:Diseases of the endocrine glands. Clinical endocrinology ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Internal Medicine ,medicine ,Congenital adrenal hyperplasia ,Testosterone ,Hydrocortisone ,media_common ,[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,030219 obstetrics & reproductive medicine ,lcsh:RC648-665 ,business.industry ,urogenital system ,Research ,rare diseases ,Micropenis ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,medicine.disease ,Sperm ,[SDV] Life Sciences [q-bio] ,[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics ,HSD3B2 ,business ,medicine.drug ,paediatric endocrinology - Abstract
Human 3 beta-hydroxysteroid dehydrogenase deficiency (3b-HSD) is a very rare form of congenital adrenal hyperplasia resulting from HSD3B2 gene mutations. The estimated prevalence is less than 1/1,000,000 at birth. It leads to steroidogenesis impairment in both adrenals and gonads. Few data are available concerning adult testicular function in such patients. We had the opportunity to study gonadal axis and testicular function in a 46,XY adult patient, carrying a HSD3B2 mutation. He presented at birth a neonatal salt-wasting syndrome. He had a micropenis, a perineal hypospadias and two intrascrotal testes. HSD3B2 gene sequencing revealed a 687del27 homozygous mutation. The patient achieved normal puberty at the age of 15 years. Transition from the paediatric department occurred at the age of 19 years. His hormonal profile under hydrocortisone and fludrocortisone treatments revealed normal serum levels of 17OH-pregnenolone, as well as SDHEA, ACTH, total testosterone, inhibin B and AMH. Pelvic ultrasound identified two scrotal testes of 21 mL each, without any testicular adrenal rest tumours. His adult spermatic characteristics were normal, according to WHO 2010 criteria, with a sperm concentration of 57.6 million/mL (N > 15), 21% of typical forms (N > 4%). Sperm vitality was subnormal (41%; N > 58%). This patient, in contrast to previous reports, presents subnormal sperm parameters and therefore potential male fertility in a 24-years-old patient with severe 3b-HSD deficiency. This case should improve counselling about fertility of male patients carrying HSD3B2 mutation.
- Published
- 2018
- Full Text
- View/download PDF
39. Looking at New Unexpected Disease Targets in
- Author
-
Héléna, Mosbah, Camille, Vatier, Franck, Boccara, Isabelle, Jéru, Olivier, Lascols, Marie-Christine, Vantyghem, Bruno, Fève, Bruno, Donadille, Elisabeth, Sarrazin, Sophie, Benabbou, Jocelyn, Inamo, Stéphane, Ederhy, Ariel, Cohen, Barbara, Neraud, Pascale, Richard, Fabien, Picard, Sophie, Christin-Maitre, Alban, Redheuil, Karim, Wahbi, and Corinne, Vigouroux
- Subjects
Adult ,Male ,lipodystrophy ,Lipodystrophy ,LMNA ,Coronary Angiography ,Lamin Type A ,Article ,Pedigree ,Electrocardiography ,Phenotype ,Cardiovascular Diseases ,cardiovascular disease ,Humans ,Female - Abstract
Variants in LMNA, encoding A-type lamins, are responsible for laminopathies including muscular dystrophies, lipodystrophies, and progeroid syndromes. Cardiovascular laminopathic involvement is classically described as cardiomyopathy in striated muscle laminopathies, and arterial wall dysfunction and/or valvulopathy in lipodystrophic and/or progeroid laminopathies. We report unexpected cardiovascular phenotypes in patients with LMNA-associated lipodystrophies, illustrating the complex multitissular pathophysiology of the disease and the need for specific cardiovascular investigations in affected patients. A 33-year-old woman was diagnosed with generalized lipodystrophy and atypical progeroid syndrome due to the newly identified heterozygous LMNA p.(Asp136Val) variant. Her complex cardiovascular phenotype was associated with atherosclerosis, aortic valvular disease and left ventricular hypertrophy with rhythm and conduction defects. A 29-year-old woman presented with a partial lipodystrophy syndrome and a severe coronary atherosclerosis which required a triple coronary artery bypass grafting. She carried the novel heterozygous p.(Arg60Pro) LMNA variant inherited from her mother, affected with partial lipodystrophy and dilated cardiomyopathy. Different lipodystrophy-associated LMNA pathogenic variants could target cardiac vasculature and/or muscle, leading to complex overlapping phenotypes. Unifying pathophysiological hypotheses should be explored in several cell models including adipocytes, cardiomyocytes and vascular cells. Patients with LMNA-associated lipodystrophy should be systematically investigated with 24-h ECG monitoring, echocardiography and non-invasive coronary function testing.
- Published
- 2020
40. Cortisol and Aldosterone Responses to Hypoglycemia and Na Depletion in Women With Non-Classic 21-Hydroxylase Deficiency
- Author
-
Laurence Pietri, Jean-François Gautier, H. Bry, Michel Azizi, Anne Blanchard, Julien Thomas, Antonin Lamaziere, Yves Le Bouc, Sylvie Salenave, Sylvie Brailly-Tabard, Sophie Christin-Maitre, Lise Duranteau, Bruno Donadille, Céline Piedvache, Aurélien Lorthioir, Peter Kamenický, Jacques Young, Philippe Chanson, Seray Genc, Marie-Laure Raffin-Sanson, CIC - HEGP (CIC 1418), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPC)
- Subjects
Hydrocortisone ,Endocrinology, Diabetes and Metabolism ,[SDV]Life Sciences [q-bio] ,Clinical Biochemistry ,Biochemistry ,chemistry.chemical_compound ,0302 clinical medicine ,Endocrinology ,Prospective Studies ,Aldosterone ,030219 obstetrics & reproductive medicine ,biology ,Incidence ,21-Hydroxylase ,Middle Aged ,Prognosis ,Female ,France ,Pseudogenes ,Cortisol secretion ,Adult ,medicine.medical_specialty ,Adolescent ,food.diet ,030209 endocrinology & metabolism ,Equivalence Trials as Topic ,Low sodium diet ,Hypoglycemia ,03 medical and health sciences ,Young Adult ,food ,Internal medicine ,Renin–angiotensin system ,medicine ,Adrenal insufficiency ,Humans ,Adrenal Hyperplasia, Congenital ,business.industry ,Biochemistry (medical) ,Insulin tolerance test ,Sodium ,medicine.disease ,chemistry ,Case-Control Studies ,biology.protein ,business ,Biomarkers ,Follow-Up Studies - Abstract
Background Non-classic 21-hydroxylase deficiency is usually diagnosed in post-pubertal women because of androgen excess. Indication of systematic steroid replacement therapy is controversial because the risk of acute adrenal insufficiency is unknown. In order to specify this risk we evaluated the cortisol and aldosterone secretions in response to appropriate pharmacologic challenges. Methods In this prospective case–control non-inferiority study we investigated 20 women with non-classic 21-hydroxylase deficiency carrying biallelic CYP21A2 mutations and with serum 17-hydroxyprogesterone (17OHP) >10 ng/mL after stimulation with Synacthen® (tetracosactrin) and 20 age- and body mass index-matched healthy women with 17OHP after Synacthen® Findings The peak serum cortisol concentration after insulin hypoglycemia was lower in patients than in controls (mean difference –47 ng/mL, 90% CI, –66, P = 0.0026). A peak serum cortisol above a cutoff value of 170 ng/mL was obtained in all controls but only in 55% of patients (P = 0.0039). Twenty-four hours after sodium depletion, blood pressure, plasma sodium, potassium, and serum aldosterone concentrations were comparable between the two groups, but patients had higher stimulated renin concentrations than controls (P = 0.0044). Interpretation Patients with non-classic 21-hydroxylase deficiency frequently display partial cortisol insufficiency and compensated defect in aldosterone secretion. Their clinical management should systematically include assessment of adrenal functions.
- Published
- 2020
- Full Text
- View/download PDF
41. Unilateral non-haemorrhagic adrenal infarction (NHAI) as a cause of abdominal pain during pregnancy
- Author
-
Fanny Chasseloup, Sophie Christin-Maitre, and N. Bourcigaux
- Subjects
Abdominal pain ,Pregnancy ,business.industry ,Anesthesia ,Medicine ,Adrenal infarction ,medicine.symptom ,business ,medicine.disease - Published
- 2019
- Full Text
- View/download PDF
42. Impact des estrogènes sur la glycorégulation
- Author
-
Bruno Fève, Camille Vatier, and Sophie Christin-Maitre
- Subjects
0301 basic medicine ,Gynecology ,medicine.medical_specialty ,Nutrition and Dietetics ,business.industry ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Internal Medicine ,medicine ,Glucose homeostasis ,Cardiology and Cardiovascular Medicine ,business - Abstract
Resume De nombreux arguments plaident en faveur d’un effet favorable des estrogenes sur la glycoregulation. Des etudes epidemiologiques ont montre que le diabete de type 1 est 7 fois plus frequent chez l’homme adulte que chez la femme. Ce ratio contraste avec celui des autres pathologies auto-immunes qui sont beaucoup plus frequentes chez la femme que chez l’homme. Les arguments therapeutiques reposent sur le fait que les traitements de menopause contenant des estrogenes diminuent la survenue d’un diabete de type 2. De plus, les rares patients decrits avec des mutations « perte de fonction » du recepteur des estrogenes ERα ou du gene de l’aromatase sont le plus souvent insulinoresistants, voire diabetiques. Des modeles animaux et des etudes in vitro ont permis de montrer que les estrogenes augmentent la secretion d’insuline par les cellules β pancreatiques, diminuent la production hepatique de glucose, diminuent la resistance peripherique a l’insuline. De plus, ils augmentent la depense energetique par un effet hypothalamique. Enfin, les estrogenes pourraient avoir un effet favorable sur la glycemie suite a des interactions avec le microbiote.
- Published
- 2016
- Full Text
- View/download PDF
43. An Application of NGS for Molecular Investigations in Perrault Syndrome: Study of 14 Families and Review of the Literature
- Author
-
Arnold Munnich, Sandrine Marlin, Justine Lerat, Erea-Noel Garabedian, Souad Gherbi, Cyril Goizet, Françoise Denoyelle, Sophie Christin-Maitre, Lionel Van Maldergem, Natalie Loundon, Didier Lacombe, Cécile Rouzier, Jean-Paul Bonnefont, Laurence Jonard, Isabelle Mosnier, and Philippe Touraine
- Subjects
0301 basic medicine ,Proband ,Genetics ,Sanger sequencing ,Mutation ,Biology ,medicine.disease_cause ,Compound heterozygosity ,Molecular biology ,03 medical and health sciences ,Dysgenesis ,symbols.namesake ,030104 developmental biology ,medicine ,symbols ,Missense mutation ,Gene ,Genetics (clinical) ,Exome sequencing - Abstract
Perrault syndrome (PS) is a rare autosomal recessive condition characterized by deafness and gonadic dysgenesis. Recently, mutations in five genes have been identified: C10orf2, CLPP, HARS2, HSD17B4, and LARS2. Probands included are presented with sensorineural deafness associated with gonadic dysgenesis. DNA was sequenced using next-generation sequencing (NGS) with a panel of 35 deafness genes including the five Perrault genes. Exonic variations known as pathogenic mutations or detected with
- Published
- 2016
- Full Text
- View/download PDF
44. Apport de la FISH sur frottis buccal dans le diagnostic et la prise en charge des patientes avec un syndrome de Turner
- Author
-
Sophie Christin-Maitre, Camille Vatier, A. Khodawardi, A. Borgel, M.C. Villy, A. Graff, H. Morel, B. Donadille, N. Bourcigaux, and Jean-Pierre Siffroi
- Subjects
Endocrinology ,Endocrinology, Diabetes and Metabolism ,General Medicine - Abstract
Le syndrome de Turner (ST) est caracterise par une perte complete ou partielle du chromosome X, diagnostique sur le caryotype lymphocytaire. Dans 50 % des cas, il existe une mosaique 45,X/46,XX. Le but de notre etude est de comparer les resultats du frottis buccal associe a une technique d’hybridation in situ par fluorescence (FISH) avec le caryotype lymphocytaire. Une etude prospective, de juillet 2017 a aout 2019, a recrute au sein d’un centre de maladies rares, 142 patientes adultes avec un ST. Un frottis buccal a ete realise, apres un consentement eclaire. Les donnees cliniques ont ete extraites de la base CEMARA. Le pourcentage de cellules 45,X etait identique entre les deux techniques chez seulement 32,4 % des patientes. La difference etait superieure a 41 % pour 12 % de la cohorte. Le pourcentage de cellules 45,X etait plus eleve dans le frottis jugal chez 53 (30,3 %) des patientes. Chez 17 (12 %) patientes, le frottis a modifie le type de l’anomalie genetique du ST, obtenu par le caryotype sanguin. Il a permis d’identifier la presence d’un chromosome Y non detecte sur les lymphocytes (n = 1) et des mosaiques chez des patientes avec une formule 45,X homogene sur les lymphocytes (n = 16). L’amenorrhee secondaire etait plus precoce lorsque le pourcentage de 45,X etait eleve sur le frottis. Le caryotype sanguin reste l’examen de reference pour le diagnostic de ST. Cependant, la FISH sur frottis buccal, technique non invasive, permet d’evaluer plus precisement la constitution chromosomique des patientes avec un ST et ainsi d’optimiser leur prise en charge.
- Published
- 2020
- Full Text
- View/download PDF
45. Monogenic forms of lipodystrophic syndromes - diagnosis, detection, and practical management considerations from clinical cases
- Author
-
Corinne Vigouroux, Marie-Christine Vantyghem, Camille Vatier, Jean-Claude Carel, Sophie Christin-Maitre, Bruno Fève, Isabelle Jéru, Jacques Beltrand, Olivier Lascols, Caroline Storey, Elise Bismuth, Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre de Recherche Saint-Antoine (CR Saint-Antoine), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-CHU Saint-Antoine [AP-HP], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), AP-HP Hôpital universitaire Robert-Debré [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Sorbonne Paris Cité (USPC), Laboratoire commun de biologie et génétique moléculaires [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'endocrinologie, gynécologie et diabétologie pédiatriques [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'endocrinologie, diabétologie et nutrition, Centre de Recherche en Nutrition Humaine - Ile de France (CRNH - IDF)-Hôpital Jean Verdier [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Sorbonne Paris Cité (USPC)-Université Paris 13 (UP13), Gestionnaire, Hal Sorbonne Université, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Sorbonne Paris Cité (USPC)-Hôpital Jean Verdier [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre de Recherche en Nutrition Humaine - Ile de France (CRNH - IDF)
- Subjects
Adult ,Male ,Pediatrics ,medicine.medical_specialty ,Lipodystrophy ,Familial partial lipodystrophy ,Berardinelli-Seip congenital lipodystrophy ,Early detection ,Consanguinity ,030204 cardiovascular system & hematology ,Metreleptin ,Congenital generalized lipodystrophy ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,GTP-Binding Protein gamma Subunits ,medicine ,Humans ,030212 general & internal medicine ,Aged ,Metabolic Syndrome ,[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,business.industry ,Infant ,General Medicine ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,medicine.disease ,3. Good health ,Fatty Liver ,chemistry ,Mutation ,Berardinelli-Seip Congenital Lipodystrophy ,Female ,business ,Acyltransferases - Abstract
International audience; BACKGROUND: Lipodystrophic syndromes are rare diseases of genetic or acquired origin characterized by partial or generalized lack of body fat. Early detection and diagnosis are crucial to prevent and manage associated metabolic dysfunctions, i.e. insulin resistance, dyslipidemia, fatty liver, and diabetes, and to provide appropriate genetic counseling. By means of several representative case studies, this article illustrates the diagnostic and management challenges of lipodystrophic syndromes.REVIEW: Berardinelli-Seip congenital lipodystrophy (BSCL) is typically diagnosed at birth, or soon thereafter, with generalized lipoatrophy and hepatomegaly secondary to hepatic steatosis. Physicians must also consider this diagnosis in adults with atypical non-autoimmune diabetes, hypertriglyceridemia, and a lean and muscular phenotype. The BSCL1 subtype due to mutations in the AGPAT2 gene can have an unusual presentation, especially in neonates and infants. Particular attention should be paid to infants presenting failure to thrive who also have hepatomegaly and metabolic derangements. The BSCL2 sub-type due to mutations in the BSCL gene tends to be more severe than BSCL1, and is characterized by greater fat loss, mild intellectual disability, earlier onset of diabetes, and higher incidence of premature death. Effective management from an earlier age may moderate the natural disease course. Partial lipodystrophies may easily be confused with common central obesity and/or metabolic syndrome. In patients with unexplained pancreatitis and hypertriglyceridemia, lipodystrophies such as familial partial lipodystrophy type 2 (FPLD2; Dunnigan type, due to LMNA mutations) should be considered. Oral combined contraceptives, which can reveal the disease by inducing severe hypertriglyceridemia, are contraindicated. Endogenous estrogens may also lead to "unmasking" of the FPLD2 phenotype, which often appears at puberty, and is more severe in females than males.CONCLUSIONS: Diet and exercise, adapted to age and potential comorbidities, are essential prerequisites for therapeutic management of lipodystrophic syndromes. Metreleptin therapy can be useful to manage lipodystrophy-related metabolic complications
- Published
- 2019
- Full Text
- View/download PDF
46. MANAGEMENT OF ENDOCRINE DISEASE: Transition of care for young adult patients with Turner syndrome
- Author
-
Sophie Christin-Maitre, Mariana Nedelcu, Laetitia Martinerie, Tiphaine Le Poulennec, Valérie Bernard, Bruno Donadille, Service d'Endocrinologie, diabétologie et endocrinologie de la reproduction [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Sorbonne Université - Faculté de Médecine (SU FM), Sorbonne Université (SU), Centre de Référence des Maladies Endocriniennes Rares de la Croissance [APHP Robert Debré], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université de Paris (UP), Physiopathologie des maladies génétiques d'expression pédiatrique (UMRS_933), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Droit et Santé (IDS - U1145), Université de Paris (UP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Maladies génétiques d'expression pédiatrique [CHU Trousseau] (Inserm U933), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Cité (UPCité), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), and Gestionnaire, Hal Sorbonne Université
- Subjects
medicine.medical_specialty ,Pediatrics ,Endocrinology, Diabetes and Metabolism ,Turner syndrome ,Population ,Karyotype ,MEDLINE ,030209 endocrinology & metabolism ,Adult care ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Internal medicine ,medicine ,Young adult ,education ,Paediatric patients ,[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,education.field_of_study ,Endocrine disease ,business.industry ,digestive, oral, and skin physiology ,General Medicine ,[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism ,medicine.disease ,3. Good health ,030220 oncology & carcinogenesis ,Transition ,business ,Neurocognitive ,Rare disease - Abstract
International audience; Turner syndrome (TS), affecting 1/2000 to 1/2500 live born girls, is a chromosomal aberration with a total or partial loss of one of the X chromosomes. The diagnosis can be established from the intra-uterine life to adulthood. TS is a chronic disease with particular morbidity and mortality. The loss to follow-up rate, during transition, between children and adult units, remains a crucial issue. This review focusses on the adolescent and young adult patients with TS. The different goals of TS transition are presented as well as some of the tools available in order to improve this transition. The involvement of the patient’s family, advocacy groups and therapeutic educational programs are discussed. A specificity concerning TS transition, as compared to other chronic diseases, relies on the fact that patients with TS may present a peculiar neurocognitive profile. They are in general more anxious than the general population. Therefore, psychological support should be offered to optimize transition. Data illustrating the beneficial impact of an organised transition of TS, from paediatric units to multidisciplinary adult care systems, within the same reference centre are presented. Further studies are required to evaluate the mid-to-long-term transition of paediatric patients with TS referred to adult units.
- Published
- 2019
- Full Text
- View/download PDF
47. Insuffisance ovarienne prématurée
- Author
-
Sophie Christin-Maitre
- Published
- 2019
- Full Text
- View/download PDF
48. Liste des collaborateurs
- Author
-
Nathalie Ambassa, Anne Bachelot, Hortense Baffet, Céline Bar, Nabila Bendris, Philippe Bouchard, Claire Bouvattier, Audrey Cartault, Maryse Cartigny-Maciejewski, Sophie Catteau-Jonard, Laurence Chardon, Nathalie Chabbert-Buffet, Sophie Christin-Maitre, Christine Cortet-Rudelli, Emile Daraï, Marie Deknuydt, Philippe Deruelle, Didier Dewailly, Armelle Dufresne, Agathe Dumont, Lise Duranteau, Aurélie Graff, Héloïse Gronier, Justine Hugon-Rodin, Linda Humbert, Wassila Karrouz, Kamila Kolanska, Brigitte Letombe, Lorraine Maitrot-Mantelet, Sylvie Manouvrier-Hanu, Maëliss Peigné, Catherine Pienkowski, Pauline Plouvier, Ingrid Plotton, Geneviève Plu-Bureau, Chloé Proust-Richard, Michel Pugeat, Véronique Raverot, Geoffroy Robin, Anne-Laure Rolland, Christine Rousset-Jablonski, Cécile Tomaszewski, Charlotte Sonigo, Pascal Vaast, Anne Vambergue, Jean-Louis Wémeau, and Jacques Young
- Published
- 2019
- Full Text
- View/download PDF
49. Cortisol and Aldosterone Responses to Insulin-Induced Hypoglycemia and Sodium Depletion in Women with Non-Classic 21-Hydroxylase Deficiency
- Author
-
Sylvie Salenave, Sylvie Brailly-Tabard, Bruno Donadille, H. Bry, Céline Piedvache, Jean-François Gautier, Lise Duranteau, Julien Thomas, Yves Le Bouc, Anne Blanchard, Laurence Pietri, M. Azizi, Sophie Christin-Maitre, Marie-Laure Raffin-Sanson, Peter Kamenicky, Aurelien Lorthioir, Jacques Young, Antonin Lamaziere, Philippe Chanson, and Seray Genc
- Subjects
Cortisol secretion ,medicine.medical_specialty ,Aldosterone ,biology ,business.industry ,food.diet ,Insulin tolerance test ,21-Hydroxylase ,Furosemide ,Low sodium diet ,medicine.disease ,chemistry.chemical_compound ,Endocrinology ,food ,chemistry ,Internal medicine ,Renin–angiotensin system ,medicine ,Adrenal insufficiency ,biology.protein ,business ,medicine.drug - Abstract
Background: Non-classic 21-hydroxylase deficiency is usually diagnosed in post-pubertal women because of androgen excess. Indication of systematic steroid replacement therapy is controversial because the risk of acute adrenal insufficiency is unknown. In order to specify this risk we evaluated the cortisol and aldosterone secretions in response to appropriate pharmacological challenges. Methods: In this prospective case-control non-inferiority study we investigated 20 women with non-classic 21-hydroxylase deficiency carrying biallelic CYP21A2 mutations and with serum 17-hydroxyprogesterone (17OHP) >10ng/mL after stimulation with Synacthen® (tetracosactrin) and 20 ageand BMI-matched healthy women with 17OHP after Synacthen®
- Published
- 2019
- Full Text
- View/download PDF
50. Insuffisance ovarienne prématurée
- Author
-
Aurélie Graff and Sophie Christin-Maitre
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.